

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 January 2002 (03.01.2002)

PCT

(10) International Publication Number
WO 02/00926 A2

(51) International Patent Classification: **C12Q 1/68**,
G01N 33/50, B01J 19/00, C12N 15/11, A61K 31/70

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, ZA, ZW.

(21) International Application Number: PCT/EP01/07472

(22) International Filing Date: 29 June 2001 (29.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
100 32 529.7 30 June 2000 (30.06.2000) DE
100 43 826.1 1 September 2000 (01.09.2000) DE

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

(71) Applicant (*for all designated States except US*): EPIGE-
NOMICS AG [DE/DE]; Kastanienallee 24, 10435 Berlin
(DE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): OLEK, Alexan-
der [DE/DE]; Schröderstrasse 13/2, 10115 Berlin (DE).
PIEPENBROCK, Christian [DE/DE]; Schwartzkopfs-
trasse 7b, 10115 Berlin (DE). BERLIN, Kurt [DE/DE];
Marienkäferweg 4, 14532 Stahnsdorf (DE).

(48) Date of publication of this corrected version:

13 June 2002

(15) Information about Correction:

see PCT Gazette No. 24/2002 of 13 June 2002, Section II

(74) Agents: SCHOHE, Stefan et al.; Boehmert & Boehmert,
Franz-Joseph-Strasse 38, 80801 München (DE).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIAGNOSIS OF DISEASES ASSOCIATED WITH SIGNAL TRANSDUCTION

CG TG



I

CG TG



II

(57) Abstract: The present invention relates to the chemically modified genomic sequences of genes associated with signal transduction, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genes associated with signal transduction which are directed against the sequence, as well as to a method for ascertaining genetic and/or epigenetic parameters of genes associated with signal transduction.

WO 02/00926 A2

Diagnosis of Diseases Associated with signal transduction

Field of the Invention

The levels of observation that have been well studied by the methodological developments of recent years in molecular biology, are the genes themselves, the translation of these genes into RNA, and the resulting proteins. The question of which gene is switched on at which point in the course of the development of an individual, and how the activation and inhibition of specific genes in specific cells and tissues are controlled is correlatable to the degree and character of the methylation of the genes or of the genome. In this respect, pathogenic conditions may manifest themselves in a changed methylation pattern of individual genes or of the genome.

The present invention relates to nucleic acids, oligonucleotides, PNA-oligomers and to a method for the diagnosis and/or therapy of diseases which have a connection with the genetic and/or epigenetic parameters of genes associated with signal transduction and, in particular, with the methylation status thereof.

Prior Art

Eukaryotic cells exist in a social context, as such, they require a system that allows inter cellular communication. Molecules such as hormones, growth factors and neurotransmitters are utilised as transmitters in cell signalling. These signals allow for the adjustment of factors such as metabolism, growth, proliferation and apoptosis that are essential to the participation of the cell in a social environment. Signal transduction can be defined as the movement of such signals from outside the cell to inside the cell. Signal transmission may be simple, as in the case of acetylcholine receptors which allow the movement of signals through ion channels on the plasma membrane surface. Alternatively, the signals may be transmitted in a more complicated manner through an intracellular signalling cascade by means of protein phosphorylation, (the addition and removal of phosphate groups by protein kinases and protein phosphatases). The system has evolved a high degree of specificity whereby the kinases and phosphatases of the system are extraordinarily precise with respect to their substrates. Signals received at the cell membrane stimulate the activity of a signal integrating complex, which then interacts with substrates, finally

leading to a phenotypic response. Furthermore, evidence is emerging that protein kinases and protein phosphatases work in concert to moderate precise, fast signal transduction that is regulated by feedback.

Signal receptors can be classified into three classes. The first class consists of receptors that span the plasma membrane and which have intrinsic enzymatic activity, such as, tyrosine kinases and guanylate cyclases. The second group consists of, receptors that are coupled to GTP-binding and hydrolyzing proteins, such as odorant receptors and some hormone receptors. The third group comprises intracellular receptors that directly affect gene transcription upon ligand binding.

Disruptions to cell signalling pathways are implicated in many diseases, including cancer, immune disease and inflammatory disorders. Therefore, the elucidation of cell signalling pathways is of considerable importance. The signalling pathways are currently far from completely understood. However, this has not deterred the use of signal transduction as a drug discovery platform, all major pharmaceutical companies currently pursue active drug discovery programs based on signal transduction.

5-methylcytosine is the most frequent covalent base modification in the DNA of eukaryotic cells. It plays a role, for example, in the regulation of the transcription, in genetic imprinting, and in tumorigenesis.

Aberrant DNA methylation within CpG islands is common in human malignancies leading to abrogation or overexpression of a broad spectrum of genes (Jones, P.A. *Cancer Res* 65:2463-2467, 1996). Abnormal methylation has also been shown to occur in CpG rich regulatory elements in intronic and coding parts of genes for certain tumours (Chan, M.F., et al., *Curr Top Microbiol Immunol* 249:75-86, 2000). Using restriction landmark genomic scanning, Costello and coworkers were able to show that methylation patterns are tumour-type specific (Costello, J. F., et al., *Nat Genet* 24:132-138, 2000). Highly characteristic DNA methylation patterns could also be shown for breast cancer cell lines (Huang, T. H.-M., et al., *Hum Mol Genet* 8:459-470, 1999). Genome wide assessment of methylation status represents a molecular fingerprint of cancer tissues.

Therefore, the identification of 5-methylcytosine as a component of genetic information is of considerable interest. However, 5-methylcytosine positions cannot be identified by sequencing since 5-methylcytosine has the same base pairing behavior as cytosine. Moreover, the epigenetic information carried by 5-methylcytosine is completely lost during PCR amplification.

A relatively new and currently the most frequently used method for analyzing DNA for 5-methylcytosine is based upon the specific reaction of bisulfite with cytosine which, upon subsequent alkaline hydrolysis, is converted to uracil which corresponds to thymidine in its base pairing behavior. However, 5-methylcytosine remains unmodified under these conditions. Consequently, the original DNA is converted in such a manner that methylcytosine, which originally could not be distinguished from cytosine by its hybridization behavior, can now be detected as the only remaining cytosine using "normal" molecular biological techniques, for example, by amplification and hybridization or sequencing. All of these techniques are based on base pairing which can now be fully exploited. In terms of sensitivity, the prior art is defined by a method which encloses the DNA to be analyzed in an agarose matrix, thus preventing the diffusion and renaturation of the DNA (bisulfite only reacts with single-stranded DNA), and which replaces all precipitation and purification steps with fast dialysis (Olek A, Oswald J, Walter J. A modified and improved method for bisulphite based cytosine methylation analysis. *Nucleic Acids Res.* 1996 Dec 15;24(24):5064-6). Using this method, it is possible to analyze individual cells, which illustrates the potential of the method. However, currently only individual regions of a length of up to approximately 3000 base pairs are analyzed, a global analysis of cells for thousands of possible methylation events is not possible. However, this method cannot reliably analyze very small fragments from small sample quantities either. These are lost through the matrix in spite of the diffusion protection.

An overview of the further known methods of detecting 5-methylcytosine may be gathered from the following review article: Rein, T., DePamphilis, M. L., Zorbas, H., *Nucleic Acids Res.* 1998, 26, 2255.

To date, barring few exceptions (e.g., Zeschnick M, Lich C, Buiting K, Doerfler W, Horsthemke B. A single-tube PCR test for the diagnosis of Angelman and Prader-Willi syndrome based on allelic methylation differences at the SNRPN locus. *Eur J Hum Genet.* 1997 Mar-Apr;5(2):94-8)

the bisulfite technique is only used in research. Always, however, short, specific fragments of a known gene are amplified subsequent to a bisulfite treatment and either completely sequenced (Olek A, Walter J. The pre-implantation ontogeny of the H19 methylation imprint. *Nat Genet.* 1997 Nov;17(3):275-6) or individual cytosine positions are detected by a primer extension reaction (Gonzalzo ML, Jones PA. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). *Nucleic Acids Res.* 1997 Jun 15;25(12):2529-31, WO 95/0669) or by enzymatic digestion (Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. *Nucleic Acids Res.* 1997 Jun 15;25(12):2532-4). In addition, detection by hybridization has also been described (Olek et al., WO 99/8498).

Further publications dealing with the use of the bisulfite technique for methylation detection in individual genes are: Grigg G, Clark S. Sequencing 5-methylcytosine residues in genomic DNA. *Bioessays.* 1994 Jun;16(6):431-6, 431; Zeschnick M, Schmitz B, Dittrich B, Buiting K, Horsthemke B, Doerfler W. Imprinted segments in the human genome: different DNA methylation patterns in the Prader-Willi/Angelman syndrome region as determined by the genomic sequencing method. *Hum Mol Genet.* 1997 Mar;6(3):387-95; Feil R, Charlton J, Bird AP, Walter J, Reik W. Methylation analysis on individual chromosomes: improved protocol for bisulphite genomic sequencing. *Nucleic Acids Res.* 1994 Feb 25;22(4):695-6; Martin V, Ribieras S, Song-Wang X, Rio MC, Dante R. Genomic sequencing indicates a correlation between DNA hypomethylation in the 5' region of the pS2 gene and its expression in human breast cancer cell lines. *Gene.* 1995 May 19;157(1-2):261-4; WO 97/6705, WO 95/5373 and WO 97/45560.

An overview of the Prior Art in oligomer array manufacturing can be gathered from a special edition of *Nature Genetics* (*Nature Genetics Supplement*, Volume 21, January 1999), published in January 1999, and from the literature cited therein.

Fluorescently labeled probes are often used for the scanning of immobilized DNA arrays. The simple attachment of Cy3 and Cy5 dyes to the 5'-OH of the specific probe are particularly suitable for fluorescence labels. The detection of the fluorescence of the hybridized probes may be carried out, for example via a confocal microscope. Cy3 and Cy5 dyes, besides many others, are commercially available.

Matrix Assisted Laser Desorption Ionization Mass Spectrometry (MALDI-TOF) is a very efficient development for the analysis of biomolecules (Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. *Anal Chem.* 1988 Oct 15;60(20):2299-301). An analyte is embedded in a light-absorbing matrix. The matrix is evaporated by a short laser pulse thus transporting the analyte molecule into the vapor phase in an unfragmented manner. The analyte is ionized by collisions with matrix molecules. An applied voltage accelerates the ions into a field-free flight tube. Due to their different masses, the ions are accelerated at different rates. Smaller ions reach the detector sooner than bigger ones.

MALDI-TOF spectrometry is excellently suited to the analysis of peptides and proteins. The analysis of nucleic acids is somewhat more difficult (Gut I G, Beck S. DNA and Matrix Assisted Laser Desorption Ionization Mass Spectrometry. *Current Innovations and Future Trends.* 1995, 1; 147-57). The sensitivity to nucleic acids is approximately 100 times worse than to peptides and decreases disproportionally with increasing fragment size. For nucleic acids having a multiply negatively charged backbone, the ionization process via the matrix is considerably less efficient. In MALDI-TOF spectrometry, the selection of the matrix plays an eminently important role. For the desorption of peptides, several very efficient matrixes have been found which produce a very fine crystallization. There are now several responsive matrixes for DNA, however, the difference in sensitivity has not been reduced. The difference in sensitivity can be reduced by chemically modifying the DNA in such a manner that it becomes more similar to a peptide. Phosphorothioate nucleic acids in which the usual phosphates of the backbone are substituted with thiophosphates can be converted into a charge-neutral DNA using simple alkylation chemistry (Gut IG, Beck S. A procedure for selective DNA alkylation and detection by mass spectrometry. *Nucleic Acids Res.* 1995 Apr 25;23(8):1367-73). The coupling of a charge tag to this modified DNA results in an increase in sensitivity to the same level as that found for peptides. A further advantage of charge tagging is the increased stability of the analysis against impurities which make the detection of unmodified substrates considerably more difficult.

Genomic DNA is obtained from DNA of cell, tissue or other test samples using standard methods. This standard methodology is found in references such as Fritsch and Maniatis eds., *Molecular Cloning: A Laboratory Manual*, 1989.

Description

The object of the present invention is to provide the chemically modified DNA of genes associated with signal transduction, as well as oligonucleotides and/or PNA-oligomers for detecting cytosine methylations, as well as a method which is particularly suitable for the diagnosis and/or therapy of genetic and epigenetic parameters of genes associated with signal transduction. The present invention is based on the discovery that genetic and epigenetic parameters and, in particular, the cytosine methylation pattern of genes associated with signal transduction are particularly suitable for the diagnosis and/or therapy of diseases associated with signal transduction.

This objective is achieved according to the present invention using a nucleic acid containing a sequence of at least 18 bases in length of the chemically pretreated DNA of genes associated with signal transduction according to one of Seq. ID No.1 through Seq. ID No.388 and sequences complementary thereto and/or sequences of a chemically pretreated DNA of genes according to table 1, and sequences complementary thereto. In the table, after the listed gene designations, the respective data bank numbers (accession numbers) are specified which define the appertaining gene sequences as unique. GenBank was used as the underlying data bank which is located at internet address <http://www.ncbi.nlm.nih.gov>.

The chemically modified nucleic acid could heretofore not be connected with the ascertainment of genetic and epigenetic parameters.

The object of the present invention is further achieved by an oligonucleotide or oligomer for detecting the cytosine methylation state in chemically pretreated DNA, containing at least one base sequence having a length of at least 13 nucleotides which hybridizes to a chemically pretreated DNA of genes associated with signal transduction according to Seq. ID No.1 through Seq. ID No.388 and sequences complementary thereto and/or sequences of a chemically pretreated DNA of genes according to table 1, and sequences complementary thereto. The oligomer probes according to the present invention constitute important and effective tools which, for the first time, make it possible to ascertain the genetic and epigenetic parameters of genes associated with signal transduction. The base sequence of the oligomers preferably contains at least one CpG dinucleotide. The probes may also exist in the form of a PNA (peptide nucleic acid) which has particularly preferred pairing properties. Particularly preferred are oligonucleotides according to the present invention in which the cytosine of the CpG dinucleotide is the 5th - 9th nucleotide from

the 5'-end of the 13-mer; in the case of PNA-oligomers, it is preferred for the cytosine of the CpG dinucleotide to be the 4th - 6th nucleotide from the 5'-end of the 9-mer.

The oligomers according to the present invention are normally used in so called "sets" which contain at least one oligomer for each of the CpG dinucleotides of the sequences of Seq. ID No.1 through Seq. ID No.388 and sequences complementary thereto and/or sequences of a chemically pretreated DNA of genes according to table 1, and sequences complementary thereto. Preferred is a set which contains at least one oligomer for each of the CpG dinucleotides from one of Seq. ID No.1 through Seq. ID No.388 and sequences complementary thereto and/or sequences of a chemically pretreated DNA of genes according to table 1, and sequences complementary thereto.

Moreover, the present invention makes available a set of at least two oligonucleotides which can be used as so-called "primer oligonucleotides" for amplifying DNA sequences of one of Seq. ID No.1 through Seq. ID No.388 and sequences complementary thereto and/or sequences of a chemically pretreated DNA of genes according to table 1, and sequences complementary thereto, or segments thereof.

In the case of the sets of oligonucleotides according to the present invention, it is preferred that at least one oligonucleotide is bound to a solid phase.

The present invention moreover relates to a set of at least 10 n (oligonucleotides and/or PNA-oligomers) used for detecting the cytosine methylation state in chemically pretreated genomic DNA (Seq. ID No.1 through Seq. ID No.388 and sequences complementary thereto and/or sequences of a chemically pretreated DNA of genes according to table 1, and sequences complementary thereto). These probes enable diagnosis and/or therapy of genetic and epigenetic parameters of genes associated with signal transduction. The set of oligomers may also be used for detecting single nucleotide polymorphisms (SNPs) in the chemically pretreated DNA of genes associated with signal transduction according to one of Seq. ID No.1 through Seq. ID No.388 and sequences complementary thereto and/or sequences of a chemically pretreated DNA of genes according to table 1, and sequences complementary thereto.

According to the present invention, it is preferred that an arrangement of different oligonucleotides and/or PNA-oligomers (a so-called "array") made available by the present invention is pre-

sent in a manner that it is likewise bound to a solid phase. This array of different oligonucleotide- and/or PNA-oligomer sequences can be characterized in that it is arranged on the solid phase in the form of a rectangular or hexagonal lattice. The solid phase surface is preferably composed of silicon, glass, polystyrene, aluminum, steel, iron, copper, nickel, silver, or gold. However, nitrocellulose as well as plastics such as nylon which can exist in the form of pellets or also as resin matrices are possible as well.

Therefore, a further subject matter of the present invention is a method for manufacturing an array fixed to a carrier material for analysis in connection with diseases associated with signal transduction in which method at least one oligomer according to the present invention is coupled to a solid phase. Methods for manufacturing such arrays are known, for example, from US Patent 5,744,305 by means of solid-phase chemistry and photolabile protecting groups.

A further subject matter of the present invention relates to a DNA chip for the analysis of diseases associated with signal transduction which contains at least one nucleic acid according to the present invention. DNA chips are known, for example, for US Patent 5,837,832.

Moreover, a subject matter of the present invention is a kit which may be composed, for example, of a bisulfite-containing reagent, a set of primer oligonucleotides containing at least two oligonucleotides whose sequences in each case correspond or are complementary to an 18 base long segment of the base sequences specified in the appendix (Seq. ID No.1 through Seq. ID No.388 and sequences complementary thereto and/or sequences of a chemically pretreated DNA of genes according to table 1, and sequences complementary thereto), oligonucleotides and/or PNA-oligomers as well as instructions for carrying out and evaluating the described method. However, a kit along the lines of the present invention can also contain only part of the aforementioned components.

The present invention also makes available a method for ascertaining genetic and/or epigenetic parameters of genes associated with the cycle cell by analyzing cytosine methylations and single nucleotide polymorphisms, including the following steps:

In the first step of the method, a genomic DNA sample is chemically treated in such a manner that cytosine bases which are unmethylated at the 5'-position are converted to uracil, thymine, or

another base which is dissimilar to cytosine in terms of hybridization behavior. This will be understood as 'chemical pretreatment' hereinafter.

The genomic DNA to be analyzed is preferably obtained from usual sources of DNA such as cells or cell components, for example, cell lines, biopsies, blood, sputum, stool, urine, cerebrospinal fluid, tissue embedded in paraffin such as tissue from eyes, intestine, kidney, brain, heart, prostate, lung, breast or liver, histologic object slides, or combinations thereof.

The above described treatment of genomic DNA is preferably carried out with bisulfite (hydrogen sulfite, disulfite) and subsequent alkaline hydrolysis which results in a conversion of non-methylated cytosine nucleobases to uracil or to another base which is dissimilar to cytosine in terms of base pairing behavior.

Fragments of the chemically pretreated DNA are amplified, using sets of primer oligonucleotides according to the present invention, and a, preferably heat-stable polymerase. Because of statistical and practical considerations, preferably more than ten different fragments having a length of 100 - 2000 base pairs are amplified. The amplification of several DNA segments can be carried out simultaneously in one and the same reaction vessel. Usually, the amplification is carried out by means of a polymerase chain reaction (PCR).

In a preferred embodiment of the method, the set of primer oligonucleotides includes at least two oligonucleotides whose sequences are each reverse complementary or identical to an at least 18 base-pair long segment of the base sequences specified in the appendix (Seq. ID No.1 through Seq. ID No.388 and sequences complementary thereto and/or sequences of a chemically pretreated DNA of genes according to table 1, and sequences complementary thereto). The primer oligonucleotides are preferably characterized in that they do not contain any CpG dinucleotides.

According to the present invention, it is preferred that at least one primer oligonucleotide is bonded to a solid phase during amplification. The different oligonucleotide and/or PNA-oligomer sequences can be arranged on a plane solid phase in the form of a rectangular or hexagonal lattice, the solid phase surface preferably being composed of silicon, glass, polystyrene, aluminum, steel, iron, copper, nickel, silver, or gold, it being possible for other materials such as nitrocellulose or plastics to be used as well.

The fragments obtained by means of the amplification can carry a directly or indirectly detectable label. Preferred are labels in the form of fluorescence labels, radionuclides, or detachable molecule fragments having a typical mass which can be detected in a mass spectrometer, it being preferred that the fragments that are produced have a single positive or negative net charge for better detectability in the mass spectrometer. The detection may be carried out and visualized by means of matrix assisted laser desorption/ionization mass spectrometry (MALDI) or using electron spray mass spectrometry (ESI).

The amplicates obtained in the second step of the method are subsequently hybridized to an array or a set of oligonucleotides and/or PNA probes. In this context, the hybridization takes place in the manner described in the following. The set of probes used during the hybridization is preferably composed of at least 10 oligonucleotides or PNA-oligomers. In the process, the amplicates serve as probes which hybridize to oligonucleotides previously bonded to a solid phase. The non-hybridized fragments are subsequently removed. Said oligonucleotides contain at least one base sequence having a length of 13 nucleotides which is reverse complementary or identical to a segment of the base sequences specified in the appendix, the segment containing at least one CpG dinucleotide. The cytosine of the CpG dinucleotide is the 5th to 9th nucleotide from the 5'-end of the 13-mer. One oligonucleotide exists for each CpG dinucleotide. Said PNA-oligomers contain at least one base sequence having a length of 9 nucleotides which is reverse complementary or identical to a segment of the base sequences specified in the appendix, the segment containing at least one CpG dinucleotide. The cytosine of the CpG dinucleotide is the 4th to 6th nucleotide seen from the 5'-end of the 9-mer. One oligonucleotide exists for each CpG dinucleotide.

In the fourth step of the method, the non-hybridized amplicates are removed.

In the final step of the method, the hybridized amplicates are detected. In this context, it is preferred that labels attached to the amplicates are identifiable at each position of the solid phase at which an oligonucleotide sequence is located.

According to the present invention, it is preferred that the labels of the amplicates are fluorescence labels, radionuclides, or detachable molecule fragments having a typical mass which can

be detected in a mass spectrometer. The mass spectrometer is preferred for the detection of the amplicates, fragments of the amplicates or of probes which are complementary to the amplicates, it being possible for the detection to be carried out and visualized by means of matrix assisted laser desorption/ionization mass spectrometry (MALDI) or using electron spray mass spectrometry (ESI).

The produced fragments may have a single positive or negative net charge for better detectability in the mass spectrometer. The aforementioned method is preferably used for ascertaining genetic and/or epigenetic parameters of genes associated with signal transduction.

The oligomers according to the present invention or arrays thereof as well as a kit according to the present invention are intended to be used for the diagnosis and/or therapy of diseases associated with signal transduction by analyzing methylation patterns of genes associated with signal transduction. According to the present invention, the method is preferably used for the diagnosis and/or therapy of important genetic and/or epigenetic parameters within genes associated with signal transduction.

The method according to the present invention is used, for example, for the diagnosis and/or therapy of solid tumours and cancer. The nucleic acids according to the present invention of Seq. ID No.1 through Seq. ID No.388 and sequences complementary thereto and/or sequences of a chemically pretreated DNA of genes according to table 1, and sequences complementary thereto can be used for the diagnosis and/or therapy of genetic and/or epigenetic parameters of genes associated with signal transduction.

The present invention moreover relates to a method for manufacturing a diagnostic agent and/or therapeutic agent for the diagnosis and/or therapy of diseases associated with signal transduction by analyzing methylation patterns of genes associated with signal transduction, the diagnostic agent and/or therapeutic agent being characterized in that at least one nucleic acid according to the present invention is used for manufacturing it, possibly together with suitable additives and auxiliary agents.

A further subject matter of the present invention relates to a diagnostic agent and/or therapeutic agent for diseases associated with signal transduction by analyzing methylation patterns of genes

associated with signal transduction, the diagnostic agent and/or therapeutic agent containing at least one nucleic acid according to the present invention, possibly together with suitable additives and auxiliary agents.

The present invention moreover relates to the diagnosis and/or prognosis of events which are disadvantageous to patients or individuals in which important genetic and/or epigenetic parameters within genes associated with signal transduction said parameters obtained by means of the present invention may be compared to another set of genetic and/or epigenetic parameters, the differences serving as the basis for a diagnosis and/or prognosis of events which are disadvantageous to patients or individuals.

In the context of the present invention the term "hybridization" is to be understood as a bond of an oligonucleotide to a completely complementary sequence along the lines of the Watson-Crick base pairings in the sample DNA, forming a duplex structure. To be understood by "stringent hybridization conditions" are those conditions in which a hybridization is carried out at 60°C in 2.5 x SSC buffer, followed by several washing steps at 37°C in a low buffer concentration, and remains stable.

The term "functional variants" denotes all DNA sequences which are complementary to a DNA sequence, and which hybridize to the reference sequence under stringent conditions and have an activity similar to the corresponding polypeptide according to the present invention.

In the context of the present invention, "genetic parameters" are mutations and polymorphisms of genes associated with signal transduction and sequences further required for their regulation. To be designated as mutations are, in particular, insertions, deletions, point mutations, inversions and polymorphisms and, particularly preferred, SNPs (single nucleotide polymorphisms).

In the context of the present invention, "epigenetic parameters" are, in particular, cytosine methylations and further chemical modifications of DNA bases of genes associated with signal transduction and sequences further required for their regulation. Further epigenetic parameters include, for example, the acetylation of histones which, however, cannot be directly analyzed using the described method but which, in turn, correlates with the DNA methylation.

In the following, the present invention will be explained in greater detail on the basis of the sequences and examples with respect to the accompanying figure without being limited thereto.

Figure 1

Figure 1 shows the hybridisation of fluorescent labelled amplicates to a surface bound oligonucleotide. Sample I being from an astrocytoma tumor sample and sample II being from an oligodendroglioma grade II tumor sample. Fluorescence at a spot shows hybridisation of the amplicate to the oligonucleotide. Hybridisation to a CG oligonucleotide denotes methylation at the cytosine position being analysed, hybridisation to a TG oligonucleotide denotes no methylation at the cytosine position being analysed. It can be seen that Sample I had a higher degree of methylation than Sample II.

Seq. ID No. 1 through Seq. ID No. 388

Sequences having odd sequence numbers (e.g., Seq. ID No. 1, 3, 5, ...) exhibit in each case sequences of the chemically pretreated genomic DNAs of different genes associated with signal transduction. Sequences having even sequence numbers (e.g., Seq. ID No. 2, 4, 6, ...) exhibit in each case the sequences of the chemically pretreated genomic DNAs of genes associated with signal transduction which are complementary to the preceding sequences (e.g., the complementary sequence to Seq. ID No.1 is Seq. ID No.2, the complementary sequence to Seq. ID No.3 is Seq. ID No.4, etc.)

Seq. ID No. 389 through Seq. ID No. 392

Seq. ID No. 389 through Seq. ID No. 392 show sequences of oligonucleotides used in Example 1.

The following example relates to a fragment of a gene associated with signal transduction, in this case, AR in which a specific CG-position is analyzed for its methylation status.

Example 1: Methylation analysis of the gene AR associated with signal transduction.

The following example relates to a fragment of the gene AR in which a specific CG-position is to be analyzed for methylation.

In the first step, a genomic sequence is treated using bisulfite (hydrogen sulfite, disulfite) in such a manner that all cytosines which are not methylated at the 5-position of the base are modified in

such a manner that a different base is substituted with regard to the base pairing behavior while the cytosines methylated at the 5-position remain unchanged.

If bisulfite solution is used for the reaction, then an addition takes place at the non-methylated cytosine bases. Moreover, a denaturing reagent or solvent as well as a radical interceptor must be present. A subsequent alkaline hydrolysis then gives rise to the conversion of non-methylated cytosine nucleobases to uracil. The chemically converted DNA is then used for the detection of methylated cytosines. In the second method step, the treated DNA sample is diluted with water or an aqueous solution. Preferably, the DNA is subsequently desulfonated at an alkaline pH value. In the third step of the method, the DNA sample is amplified in a polymerase chain reaction, preferably using a heat-resistant DNA polymerase. In the present case, cytosines of the gene AR are analyzed. To this end, a defined fragment having a length of 460 bp is amplified with the specific primer oligonucleotides GTAGTAGTAGTAGTAAGAGA (Sequence ID 389) and ACCCCCTAAA TAATTATCCT (Sequence ID No. 390). This amplificate serves as a sample which hybridizes to an oligonucleotide previously bonded to a solid phase, forming a duplex structure, for example TGTTATTTTCGAGAGAGGT (Sequence ID No. 391), the cytosine to be detected being located at position 157 of the amplificate. The detection of the hybridization product is based on Cy3 and Cy5 fluorescently labelled primer oligonucleotides which have been used for the amplification. A hybridization reaction of the amplified DNA with the oligonucleotide takes place only if a methylated cytosine was present at this location in the bisulfite-treated DNA. Thus, the methylation status of the specific cytosine to be analyzed is inferred from the hybridization product.

In order to verify the methylation status of the position, a sample of the amplificate is further hybridized to another oligonucleotide previously bonded to a solid phase. Said oligonucleotide is identical to the oligonucleotide previously used to analyze the methylation status of the sample, with the exception of the position in question. At the position to be analysed said oligonucleotide comprises a thymine base as opposed to a cytosine base i.e TGTTATTTTGAGAGAGGT (Sequence ID No. 392). Therefore, the hybridisation reaction only takes place if an unmethylated cytosine was present at the position to be analysed.

Example 2: Diagnosis of diseases associated with signal transduction

In order to relate the methylation patterns to one of the diseases associated with signal transduction, it is initially required to analyze the DNA methylation patterns of a group of diseased and of a group of healthy patients. These analyses are carried out, for example, analogously to Example 1. The results obtained in this manner are stored in a database and the CpG dinucleotides which are methylated differently between the two groups are identified. This can be carried out by determining individual CpG methylation rates as can be done, for example, in a relatively imprecise manner, by sequencing or else, in a very precise manner, by a methylation-sensitive "primer extension reaction". It is also possible for the entire methylation status to be analyzed simultaneously, and for the patterns to be compared, for example, by clustering analyses which can be carried out, for example, by a computer.

Subsequently, it is possible to allocate the examined patients to a specific therapy group and to treat these patients selectively with an individualized therapy.

Example 2 can be carried out, for example, for cancer and solid tumours.

Table 1

List of preferred genes associated with signal transduction according to the invention

Gene	Genbank Entry No. (http://www.ncbi.nlm.nih.gov)
DYRK4	Y09305
EPHA5	L36644
NEK3	Z29067
PCTK3	X66362
PRKAR1B	M65066
PRKM3	M84490 Z11696
PRKMK2	L11285
SH3D1B	U61167
ZAP70	L05148
PIK3CA	NM 006218
ADRBK1	NM 001619
AKT1	NM 005163
AKT2	NM 001626
ARHA	NM 001664
BMPR2	NM 001204
CHN1	NM 001822
CHN2	NM 004067
CLK3	NM 003992

Gene	Genbank Entry No. (http://www.ncbi.nlm.nih.gov)
CNK	NM 004073
CSK	NM 004383
CSNK1D	NM 001893
CTNNB1	NM 001904
CTNND2	NM 001332
DGKG	NM 001346
DRG2	NM 001388
DVL3	NM 004423
DYRK3	NM 003582
EFNA1	NM 004428
EPHA4	NM 004438
EPHB3	NM 004443
ERBB4	NM 005235
GRB2	NM 002086
HCK	NM 002110
AATK	NM 004920
MADH3	NM 005902
MAPKAPK2	NM 004759
MAP3K3	NM 002401
ROR1	NM 005012
ROR2	NM 004560
PDE4B	NM 002600
PDPK1	NM 002613
B56	NM 006245
PRKACG	NM 002732
PRKAG1	NM 002733
PRKARIA	NM 002734
PRKCA	NM 002737
PRKCG	NM 002739
PRKCZ	NM 002744
PRKG1	NM 006258
MAPK1	NM 002745
MAPK10	NM 002753
MAPK13	NM 002754
MAPK6	NM 002748
MAPK9	NM 002752
PTK2	NM 005607
PTK2B	NM 004103
RGS7	NM 002924
RHOK	NM 002929
RYK	NM 002958
SFN	NM 006142
STAT1	NM 007315
STAT2	NM 003877
STK3	NM 006281
TIAM1	NM 003253

Gene	Genbank Entry No. (http://www.ncbi.nlm.nih.gov)
TTK	NM 003318
TYRO3	NM 006293
UBE1L	NM 003335
YES1	NM 005433
MAP3K12	NM 006301

Claims

1. A nucleic acid comprising a sequence at least 18 bases in length of a segment of the chemically pretreated DNA of genes associated with signal transduction according to one of the sequences taken from the group of Seq. ID No.1 to Seq. ID No.388 and sequences complementary thereto.
2. A nucleic acid comprising a sequence at least 18 base pairs in length of a segment of the chemically pretreated DNA of genes associated with signal transduction according to one of the sequences according to the genes CD20 DYRK4 (Y09305),EPHA5 (L36644), NEK3 (Z29067), PCTK3 (X66362), PRKAR1B (M65066), PRKM3 (M84490) (Z11696), PRKMK2 (L11285), SH3D1B (U61167), ZAP70 (L05148), PIK3CA (NM_006218), ADRBK1 (NM_001619), AKT1 (NM_005163), AKT2 (NM_001626), ARHA (NM_001664), BMPR2 (NM_001204), CHN1 (NM_001822),CHN2 (NM_004067), CLK3 (NM_003992), CNK (NM_004073), CSK (NM_004383), CSNK1D (NM_001893), CTNNB1 (NM_001904), CTNND2 (NM_001332), DGKG (NM_001346), DRG2 (NM_001388), DVL3 (NM_004423), DYRK3 (NM_003582), EFNA1 (NM_004428), EPHA4 (NM_004438), EPHB3 (NM_004443), ERBB4 (NM_005235), GRB2 (NM_002086), HCK (NM_002110), AATK (NM_004920), MADH3 (NM_005902),MAPKAPK2 (NM_004759), MAP3K3 (NM_002401), ROR1 (NM_005012), ROR2 (NM_004560), PDE4B (NM_002600), PDPK1 (NM_002613), B56 (NM_006245), PRKACG (NM_002732), PRKAG1 (NM_002733), PRKAR1A (NM_002734), PRKCA (NM_002737), PRKCG (NM_002739), PRKCZ (NM_002744), PRKG1 (NM_006258), MAPK1 (NM_002745), MAPK10 (NM_002753), MAPK13 (NM_002754), MAPK6 (NM_002748), MAPK9 (NM_002752), PTK2 (NM_005607), PTK2B (NM_004103), RGS7 (NM_002924), RHOK (NM_002929), RYK (NM_002958), SFN (NM_006142), STAT1 (NM_007315), STAT2 (NM_003877), STK3 (NM_006281), TIAM1 (NM_003253), TTK (NM_003318), TYRO3 (NM_006293),UBE1L (NM_003335), YES1 (NM_005433), MAP3K12 (NM_006301) and sequences complementary thereto.
3. An oligomer, in particular an oligonucleotide or peptide nucleic acid (PNA)-oligomer, said oligomer comprising in each case at least one base sequence having a length of at least 9 nucleotides which hybridizes to or is identical to a chemically pretreated DNA of genes associ-

ated with signal transduction according to one of the Seq ID Nos 1 to 388 according to claim 1 or to a chemically pretreated DNA of genes according to claim 2 and sequences complementary thereto.

4. The oligomer as recited in Claim 3; wherein the base sequence includes at least one CpG dinucleotide.
5. The oligomer as recited in Claim 3; characterized in that the cytosine of the CpG dinucleotide is located approximately in the middle third of the oligomer.
6. A set of oligomers, comprising at least two oligomers according to any of claims 3 to 5.
7. A set of oligomers as recited in Claim 6, comprising oligomers for detecting the methylation state of all CpG dinucleotides within one of the sequences according to Seq. ID Nos. 1 through 388 according to claim 1 or a chemically pretreated DNA of genes according to claim 2, and sequences complementary thereto.
8. A set of at least two oligonucleotides as recited in Claim 3, which can be used as primer oligonucleotides for the amplification of DNA sequences of one of Seq. ID 1 through Seq. ID 388 and sequences complementary thereto and/or sequences of a chemically pretreated DNA of genes according to claim 2, and sequences complementary thereto and segments thereof.
9. A set of oligonucleotides as recited in Claim 8, characterized in that at least one oligonucleotide is bound to a solid phase.
10. Use of a set of oligomer probes comprising at least ten of the oligomers according to any of claims 6 through 9 for detecting the cytosine methylation state and/or single nucleotide polymorphisms (SNPs) in a chemically pretreated genomic DNA according to claim 1 or a chemically pretreated DNA of genes according to claim 2.
11. A method for manufacturing an arrangement of different oligomers (array) fixed to a carrier material for analyzing diseases associated with the methylation state of the CpG dinucleo-

tides of one of the Seq. ID 1 through Seq. ID 388 and sequences complementary thereto and/or chemically pretreated DNA of genes according to claim 2, wherein at least one oligomer according to any of the claims 3 through 5 is coupled to a solid phase.

12. An arrangement of different oligomers (array) obtainable according to claim 11.
13. An array of different oligonucleotide- and/or PNA-oligomer sequences as recited in Claim 12, characterized in that these are arranged on a plane solid phase in the form of a rectangular or hexagonal lattice.
14. The array as recited in any of the Claims 12 or 13, characterized in that the solid phase surface is composed of silicon, glass, polystyrene, aluminium, steel, iron, copper, nickel, silver, or gold.
15. A DNA- and/or PNA-array for analyzing diseases associated with the methylation state of genes, comprising at least one nucleic acid according to one of the preceeding claims.
16. A method for ascertaining genetic and/or epigenetic parameters for the diagnosis and/or therapy of existing diseases or the predisposition to specific diseases by analyzing cytosine methylations, characterized in that the following steps are carried out:
 - in a genomic DNA sample, cytosine bases which are unmethylated at the 5-position are converted, by chemical treatment, to uracil or another base which is dissimilar to cytosine in terms of hybridization behavior;
 - fragments of the chemically pretreated genomic DNA are amplified using sets of primer oligonucleotides according to Claim 8 or 9 and a polymerase, the amplicates carrying a detectable label;
 - amplicates are hybridized to a set of oligonucleotides and/or PNA probes according to the Claims 6 and 7, or else to an array according to one of the Claims 12 through 15; the hybridized amplicates are subsequently detected.
17. The method as recited in Claim 16, characterized in that the chemical treatment is carried out by means of a solution of a bisulfite, hydrogen sulfite or disulfite.


18. The method as recited in one of the Claims 16 or 17, characterized in that more than ten different fragments having a length of 100 - 2000 base pairs are amplified.
19. The method as recited in one of the Claims 16 through 18, characterized in that the amplification of several DNA segments is carried out in one reaction vessel.
20. The method as recited in one of the Claims 16 through 19, characterized in that the polymerase is a heat-resistant DNA polymerase.
21. The method as recited in Claim 20, characterized in that the amplification is carried out by means of the polymerase chain reaction (PCR).
22. The method as recited in one of the Claims 16 through 21, characterized in that the labels of the amplicates are fluorescence labels.
23. The method as recited in one of the Claims 16 through 21, characterized in that the labels of the amplicates are radionuclides.
24. The method as recited in one of the Claims 16 through 21, characterized in that the labels of the amplicates are detachable molecule fragments having a typical mass which are detected in a mass spectrometer.
25. The method as recited in one of the Claims 16 through 21, characterized in that the amplicates or fragments of the amplicates are detected in the mass spectrometer.
26. The method as recited in one of the Claims 24 and/or 25, characterized in that the produced fragments have a single positive or negative net charge for better detectability in the mass spectrometer
27. The method as recited in one of the Claims 24 through 26, characterized in that detection is carried out and visualized by means of matrix assisted laser desorption/ionization mass spectrometry (MALDI) or using electron spray mass spectrometry (ESI).

28. The method as recited in one of the Claims 16 through 27, characterized in that the genomic DNA is obtained from cells or cellular components which contain DNA, sources of DNA comprising, for example, cell lines, biopsies, blood, sputum, stool, urine, cerebral-spinal fluid, tissue embedded in paraffin such as tissue from eyes, intestine, kidney, brain, heart, prostate, lung, breast or liver, histologic object slides, and all possible combinations thereof.
29. A kit comprising a bisulfite (= disulfite, hydrogen sulfite) reagent as well as oligonucleotides and/or PNA-oligomers according to one of the Claims 3 through 5.
30. The use of a nucleic acid according to Claims 1 or 2, of an oligonucleotide or PNA-oligomer according to one of the Claims 3 through 5, of a kit according to Claim 29, of an array according to one of the Claims 12 through 15, of a set of oligonucleotides according to one of claims 6 through 9 for the diagnosis of diseases.
31. The use of a nucleic acid according to Claims 1 or 2, of an oligonucleotide or PNA-oligomer according to one of Claims 3 through 5, of a kit according to Claim 29, of an array according to one of the Claims 12 through 15, of a set of oligonucleotides according to one of claims 6 through 9 for the therapy of diseases.

1/1

BEST AVAILABLE COPY

Figur 1



Sequence listing

<110> Epigenomics AG

<120> Diagnosis of Diseases Associated with
Signal Transduction

<160> 392

<210> 74

<211> 13133

<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<220>

<221> unsure

<222> (8922)

<400> 74

tttggaaattt	agataggaaa	tataaataga	aaagaagtgg	tgtttgttta	aatgggtgtat	60
aagtaattttt	taataatatt	atcgttttta	attttatatt	tataaaattt	tatttggttt	120
gagtaaaagt	tataaaatat	gtgattttga	aaaatggatt	ttataaatgt	tatgtttaat	180
agataagatg	gtttgttgta	tatatttagg	gttttttacg	gagatagaga	ttttaatttt	240
attattttat	atttaaatatt	tagtataggg	tttgggtatat	tataggtgtt	ttatttaatt	300
tatatattgat	ataaaaaatga	aataggatat	agaaaaaaat	atgtatatat	aagattttat	360
gttgggttttt	ttattttttag	attatagtat	tttttatatt	ttatttagta	gtttattaat	420
atgaagatag	ggattatggt	tgttttgttt	attatttttt	ttttaaatatt	tagagtttta	480
ttttgaaaaat	attttatttat	tagtattttt	tttttttttg	aaaatttgat	gaaatttaag	540
tgtatatatg	atttagtgat	aaaaataaaa	attttggtgt	tttagatttg	aaagattttt	600
atgtagatgt	gtattatagt	attttatgaa	tttttgattt	atttttaaaa	gttttttaggt	660
tttattaatt	gtaataatta	tttaaggtat	ttagtttaat	aaattaagta	acgattatat	720
tgtttggtttt	tttttcggag	gggttagtgg	tttagttttt	tgaagatggt	tatttttata	780
agtttggtggg	atattttagat	ttttaaatag	gaattttaag	aagtaatttt	tgtttttaggt	840
atgtatgtta	tttttgaaata	tttttgttta	aattttatta	atgggtgtgaa	ttaagggatt	900
ttagtttttt	attgagaatt	tttttgggat	tttttttaag	tattatgggt	gttgagaggt	960
aaggggtagg	agaggattgg	tagttaggat	ttttttttag	ttaggaattt	ttgttttgga	1020
taattttttag	ttttaaaagta	gtttggtagg	tgattttttgt	atgaaatttt	atattatttt	1080
gttatttataa	tttatttttat	ttagttaatt	ggtatttaata	gaagggttgg	tgtttaaagt	1140
atagagtttt	tgtttttttag	gaattttata	tttaattagat	gaagtttatt	gttattagta	1200
tttttttttat	tattttttttt	taaattttat	ttttgggggt	ttatatatta	ttgaaagagt	1260
agaaggggtt	tgtatatgta	atataagta	ttaaaatatg	atttgggaat	atttggatta	1320
taaaatgaaa	ttttaatttt	tttttattag	tagattaaga	cgtttatatt	ttttttattg	1380
gatatataat	atgtataatg	attatgtgga	gtgtgagttt	tttttttggt	tattttta	1440
taaaataaaa	tagaagataa	tatttggggt	ttgtttgatt	gtgattttat	aggtttaggg	1500
atattatttt	ttagattttat	aattgagttt	ttttattata	tttatagatg	atattttatg	1560
ttaggtgatt	ttatatattaa	taagagtagt	tagaaagggt	attttatttt	tgttttatgt	1620
taaaagtagg	gtagtttata	aaaatgaatt	aggtaagttt	tgggtatata	taaaagaggt	1680
ataggtttgt	ttaatgtttt	tttttttttag	tttcgttttt	tgtatttttt	tttgtttatt	1740
gtgggttttt	aaatattaga	taataaaagga	gtttgaatta	aaatattttt	tttttataga	1800
attatttttt	ttagagtggg	gtgggtgat	tttagtagaa	aaattttatat	tatttgtata	1860
tatgtttata	aaagtataaa	gtttttttatt	aggataaaa	taatttttggg	gttttagaga	1920
tttttaaaaa	tatagtaaa	taaaaattaag	ttttagaaat	ttatttttaag	taatttttgt	1980
gttttcgtata	atttaatat	tgattataaa	tgtttttagta	attaaaatta	acgagattga	2040
taagaaacga	ttatttttta	tattttta	tgtttttttt	tgggtttttt	tgtagtatta	2100
attattattt	aattttaggt	ggatttaaga	gttttttagg	gttttaattt	cgattttttt	2160
ggtttttttat	ttttataatt	ttttgtaatt	gattttgaa	atagtttagg	ttttagta	2220
tgttttatggt	ttgatgtttg	cgtatttggt	ttttgagttt	agatttttta	aggtgttatt	2280
ttttgagtgg	aagatatata	tatttaatta	tcgattagtt	ttttttttta	taagtaattt	2340

10613524 seq id 74.txt

aaatttaatt	tatgattttt	ttaataaatt	agttttttat	ttttataatt	ttttattttt	2400
gataaaaaga	agggtttttt	tttatgtgtt	atttaggtta	tttatttgcg	aatgaatttt	2460
tagtattgtg	tgtttggaag	attttaatat	tttttttatt	tttttaagtt	attaagaaga	2520
tgtattatta	ttatttttagg	ttttttttat	taatattgtt	ttattttatt	tttttgatgt	2580
tttttattgg	gataattgag	gtagtatcgt	aatatgtttt	tttgttttta	agtttagaat	2640
tttttaaaatt	ttttttttat	agtgttttta	gagtttgatt	taaaagtttt	aatttgagat	2700
tatttttgggt	tttggtttaag	gtttgtgggt	gtaattttat	tttatagtta	atgtaagaat	2760
ttattagtaa	gaatataagg	ttttaaaatg	tagagggtta	atgatcggag	tttttttatt	2820
tttattaatt	attgttattt	ttttttttta	gagaataaag	ttagatagtt	taggatttta	2880
aaaatattat	ataattttat	atttttttgt	tttttagtgag	gttaggtttt	ataatggtag	2940
atttttagtt	agatatatat	taaatgattt	agtttttatta	tttattaaat	gtgtgattta	3000
gggtaattta	ttttattttt	gttaatttta	gtgtttttgt	ttgtaaaaag	aaggtaataa	3060
agttatttta	ttagggtttt	taggggggatt	aaataaggta	atatgtgtta	agtgtttagt	3120
agttagttta	tgagagtatt	attattgggt	tttttagata	ttttttgtta	tttttttttt	3180
tatatttagg	tgattttatt	ttttatttat	ttttttttat	tgtaattgtt	ttaatattag	3240
atgtatttat	ttgggtgtga	gtaatttttag	gggtgggttt	ttttttatgt	ttttaagttt	3300
ttattaatat	aaatttaggt	atatagttaag	tttttaataa	atatttttgg	gatggaagaa	3360
tatatgttaa	tagatttttt	ttgttaattt	ttgttttttt	tggaagtgtt	tttgagaatt	3420
atatgtgtga	tttttataag	gaaatatgaa	gttaagggtt	aggaatttaa	gaaacgtttt	3480
tggtgtattta	agttataaga	cgttaggttt	gtagtggatt	cgtatagatt	tggaagttta	3540
ggatttttta	gtataaagta	tttgtagtag	atatattaat	taaattatgt	ataaaatatt	3600
tgtaataaat	atattaatta	aatattttaa	agtaatatat	gtaattttta	aagtttttta	3660
gatgttagag	atttatttga	gaagttttag	taaaagaaga	tttggaattt	taaatattgt	3720
aggattttta	aattataatt	aagtttaaaa	gtataattaa	ttgatttata	aaaaatgggg	3780
tagagagtatt	gggtgggggtg	ttgaggggag	agaaatgtta	gaatattttt	agaatacgtta	3840
tgtaagattg	atattataaa	tttaaggata	ttaaaaattt	ttttttttag	tttagttttt	3900
tgaagtgtga	gattatgggt	tatttcgata	tgtaaatgta	tagtatagtg	tgtgttatat	3960
ttaaaaatat	atattgaggt	cgggtatagg	gggttaattt	tgtaatttta	gtattttggg	4020
aggttgaggt	agggtggatta	tttgagggtta	ggagttttata	attaatttgg	ttaatatggt	4080
gaaattttat	ttttattaaa	aatataaaaa	ttagtttaggt	atggtggcgg	gtgtttgtta	4140
ttttagttat	ttgggtgggt	aaggtaagag	aatcgtttga	atttcggagg	cggaggtttt	4200
agtgaagtcga	gatgggttta	ttgtatttta	gtttgggtta	tagagtgaga	tttcgtttta	4260
aaaaaataaa	ataaaaataa	ataaaaaata	aaaatataat	ataattgtta	aaatagttat	4320
aatttatggg	ttcgaattga	gagatttcta	aagggttttt	tgattattaa	gtattttggt	4380
attaaatatt	atataaaaaat	aatagtttta	ttagtttggg	agtttttatt	ttttttaata	4440
agaaaatggg	aaatagtaga	tattttattg	tgataatagt	tttgggcgtt	taaaaatttt	4500
tttgaaagtt	ttttagaatt	gttgtagatt	attatggtaa	tagaattgag	tttaaaaaga	4560
ttggaatttt	agtttttttt	taaaattttt	gtagttttgt	gtgggtttgt	tagaaaagaa	4620
aatgtttatt	tttttttttt	taaaatattg	ttatttttta	aaatgtgtat	tttaatttga	4680
attattttat	aaaggtaaaa	ttgataattg	gagtggttta	tatagtaaaa	tagttataaa	4740
agttatatat	attttaatat	ttttgaattt	aaaaatattt	ttattaataa	ttattaatta	4800
atattaatag	aaaaataata	ggaagtaaga	tagtgattgg	gtatattttt	tttttttata	4860
taaatagaaa	taattaaagt	gtaaaaataa	ttatatatgg	agataataaa	taaaagggtta	4920
atgggtttaga	taaattttta	agtttataat	ttttataatt	atatatttta	tttgttttat	4980
atattatttg	taagagaaaa	tgtgggtaag	tttttatgat	aagattattt	ttattttttt	5040
aatgtttttt	cgttttttat	ttatttttaga	agtttttttt	agggtgaatt	attttggaaa	5100
taataattaa	aaattttata	aaatttgata	gatatatggg	aatatggatt	tataaagggt	5160
tttgatttta	taatgaggtt	agtataattt	tttagaatta	gtagttttta	ttagtatatt	5220
aaaattagat	gtaggaggat	gtaggttttt	attttgggtt	tgatatgaat	tggttgggga	5280
attttgatga	aattagtatt	ttcgttttag	tttgtttttt	tatttataaa	ttgaaagaat	5340
agaattagat	aaattttgtg	gtttttgtta	ttttttttgt	attatgaaat	ttgttatgtt	5400
atagaaaata	aattaaaatt	aaattattat	cgaaatttta	atttatattt	ttaaaagtta	5460
gtatttaata	attaatagta	tatcgaagtt	tatatatacg	ttaaaaataa	gtaaaatttg	5520
tatatgttat	agtaaaaata	agggttttat	tatgaggagt	attgagaagt	atattcgtat	5580
tttttttttt	ttggtgtatt	atagggtttt	tttttagtgg	agattttgtc	ttttatttat	5640
ttttattata	tgtattttta	ttgtaaaagag	gttttgattta	agtaaaagttt	attttttata	5700
aattggaatt	tatatgtaaa	ttaaatagtt	tttttttttag	tttatattat	gttatgtgat	5760
tatattaata	tatagtaaaa	aattgggtat	tatatatttt	aaattgttag	atgattttta	5820
ataaaaaaat	ttaaattttt	aaaatttaag	gtagtttttt	aaatattatt	gtgataagaa	5880
tattttaatag	taatatatag	aattatttat	ttttatttat	tatttatagt	ttaatatagg	5940
ttagttaatt	tttgttaaat	gaatttttag	tttttgggat	tagatgtgtt	aggatagaga	6000
gatagataga	gggaggggga	agatagtaat	agtaataaaa	tattttttta	cgaaatttgt	6060
atatattttt	ttaagtttaa	taggtgttaat	tatagtttag	atattttttt	atagtttttt	6120

10613524 seq id 74.txt

gataaataag	tttttttata	atatatgttt	ttagagtatt	ttttttgtag	atcggagatg	6180
gttttttttt	taagaattta	atttttatnt	agtaaataaa	attaattttt	agtaagtttt	6240
ttttatatag	aattattttta	ggttgttttt	gtggaaaatt	taattgggaa	aaaaagattt	6300
ttaaattatt	atttttttta	agtgtagatt	tttttaggt	tggttattat	tatttaaggg	6360
tgatttttgg	gagttgagaa	aaggtatatg	tttttagtca	atttagtttg	ttagtttttcg	6420
tagttattag	taattagttt	tacgttggtt	tttttttttt	tagagattat	agtatttggt	6480
aggtgttttt	ttttttttat	ttttaaagta	acgtttgttt	tttttttttg	aataatgttt	6540
aattgtagaa	ttttataggg	gtggtttgtt	ttgattgttg	cggcggtttt	tatttttggt	6600
aatgttgatt	ataatttttg	ttgtgtttta	attttagtag	tttataaaat	atgtttatat	6660
acgcggggga	taattggcga	tgttttttgt	tggttggagt	taggtttggg	aggttttttg	6720
ggggatcgat	ttttcgggta	ggtcggtttg	gttgtttttt	aatacgtatt	tgtttttata	6780
aataatttatt	atttcagggg	aggtggggga	aggatagaga	tgtttatcgg	gttagggaag	6840
ggaatttttg	gatgtaagga	cgaaaaatga	ggaaaagaag	aaagtagtaa	ggaggaagtt	6900
tttaggaaga	ggaggttatg	gggtgggcgag	ttttggaggg	gaagtaaggg	gtttacgtta	6960
cgaatttttt	tttgtggttg	tagttttggg	ttcgtttaat	ttaattaggg	cggcgtcgac	7020
gagagattat	cggttcagag	cgtgggggtg	tttgtatttc	gatttttttt	ttttcggcgt	7080
tagatttttt	taagttcggg	tgtttcgggt	tggggttttt	ttcgttttta	tcgttcgggt	7140
cgttcgcggg	ttgggtttta	tcgtgtgggt	tcggcggtta	gcgttggttg	ttcggagagg	7200
cggtagggcg	atggggggag	gcgggttagt	ttttatttcg	tttcgggttg	tttttgatc	7260
gagtttcggg	gaagtttgaa	gttgacgaac	ggcgttggtt	ttatttcggt	ttggaagtta	7320
cgtgcgggag	gagataaaag	agggtagggg	gggagaaagt	tatttagatt	ttttttttaa	7380
tttcgttggg	tagcgataat	ttttttttta	agaaagacgg	aggaagagat	cggggtagta	7440
aaaacggggc	ttcgggttac	ggtttttttag	cgtatattta	cgggcggggc	gcgggtagtt	7500
gtaaacgttaa	gtgggggttt	ggcgcgcgag	ttcgcgattc	ggcgggggag	tcgggtcgcg	7560
tcggggttag	gcgggtttacg	ttgtagacgg	ttagttagtc	ggaggtgggt	ttggatagtt	7620
gagtagggag	ttacggttac	gttaagtttc	gggtagcgta	gggcggggcg	gtaggtttg	7680
acggttttcg	ttcgggtttt	cggtaggtag	aagttttttc	gggtcgaggg	tttttcgcgg	7740
aggggttttc	ggggtcgcgt	ataattttgt	atggagttcg	gggcgcgtcg	ttcgttcggg	7800
ggtttttttc	cgtcgcgtcg	tcgattttgt	tcgaggtttc	gtaggtagcg	gtcgttcgcg	7860
ttatatgggt	tgtttagggg	cggcgggggg	tcggggatgc	ggcgcggcgg	tacggttttt	7920
ttatcgggtc	gttaggcggc	gggagcggcg	gtcgaaggtt	ttttggttaa	tatggtcggt	7980
ggagaggaaa	atgtattttta	gggttgctgt	cgtcgtcgtc	ggttttgttg	ttatttttgg	8040
cggtcgtcgt	cgtcgttttt	cggtcgtttt	tcgcgcgggt	tttcggcggt	tcgtcgtcgt	8100
ttcgcgtttg	ttatagtttag	atatatatag	tttattgtat	tttttcggtc	ggggttcgtc	8160
gtcgcgagtt	tttcgttttt	tttttcgtcg	tcgttttttt	ttttttcggg	cggttgtagt	8220
atttttcggt	tcgtgtatat	gttttcgttt	tttttcgcgc	tcgcgggttt	tttcgttttt	8280
tttatatagg	ggcgcgggga	gttggaagcg	ttgcgaggtt	cgaagatcgt	ttggttcggg	8340
agtttttttc	gggttcgcgc	gcgcgcgttt	tcgcgtattt	atatataggc	gtcggcgcg	8400
ggtttcgttt	tcgtcgtttt	tcgtcgtttt	ttttcgtcgt	cgtaggtttc	gttttcggtt	8460
ttttcggtcg	cggttacgta	tattttattt	ttatttaatt	tttcgttcgg	tttttttttag	8520
tttttcgggt	tgccgcgtagt	cgttttttcg	tttttcggaa	aattcggcgg	ttttcgttcg	8580
tttttttttc	tttttttcgg	ttatttgtat	tgtttttttt	ggtttttatt	cggcgatttt	8640
tttttttttt	cggtttcgcg	gcgttttttt	tttgtttttt	agtttaattt	atcgttggtg	8700
tttttcggtc	gaaagcgtcg	tagagatttt	ttttttgtta	tgctattttt	taaatataaa	8760
tgtattttta	gttttttcgaa	ttgaatggtt	gtttatagtt	agtattgttt	tttcgttttt	8820
ttatttttgg	tgtttagcgat	ttagttattt	tttttttttt	aattattatg	tagatatattt	8880
agttgggcga	gggttatttt	ggcgaggtaa	gttcgggagg	gncggtcggt	gagttcgttg	8940
ttattttgagta	ggggcgaaag	aggggggtgt	ttttttattt	ttattatata	tttttttcgg	9000
tttattgata	ttaaagtatc	gttcgttagt	cgttaggata	aggggaggtta	gagaggcgcg	9060
tgtggacggg	agttggggaa	gtagttggtt	gtgggttggt	aggtaaaaaat	aaatattaga	9120
gatatattttt	atttttttat	aatttcgagt	tttttttttg	cgcggttatt	gggagagata	9180
tatttttttt	ttagttttgc	ggtgagggag	cgatatttcg	aatttttttt	attttattcg	9240
atatattttt	tttttttttt	ttttttaaga	tacgtggaga	atttttttgt	tttttttatt	9300
cgttatatat	aatttttttt	ttttttgaag	attaaaaaaa	aattgttttt	tcgttttata	9360
ttcgcgtttt	gtcgtgcgtg	gtatatagtg	cgttttttgt	taaagggttat	aggttttgtt	9420
atttttaattg	tgagaggagg	tgggggtggga	aagtttcgata	aatttcggat	gacggggtag	9480
agttatgtta	tgtatttttt	tttcgagagg	tgtttagttt	ttgaagtttt	tttgggggtta	9540
gggggtttatt	atgtttttgt	tcgttcgagt	atttttggtt	tttggttgga	tttattgtgt	9600
aggttcgaat	tagttagat	tttagttgga	agggagttat	tttttcggga	gtttttattta	9660
ttttattggt	tgtaaattgt	tatagtaatt	ttttatagag	cgtatttcgta	gtttttatata	9720
aacgtttaaaa	attgtttttaa	ggtatagtgt	gatttttttt	gagttttttg	gatttttttaa	9780
gagggttttta	agttagggtt	attgggagag	ggaattttgt	ataaaaagaa	tttttttttag	9840
tattacgttt	ttttaaataa	aataaaaataa	aataaaaataa	aataaaaatat	tttttcgggg	9900

10613524 seq id 74.txt

ttttttttta	ataaagtaga	tttataagtaa	aataatttaa	taatatgttt	ttagaggaat	9960
tatgatttga	attgatttta	gtaagaaata	tttttttatg	tttgttattg	gcgattatta	10020
tattttaaatt	tatatgcgga	agtataattta	gtgttttagaa	tcgattaaaa	gaaaagggtt	10080
attaagtagt	agagatgata	ttagaatcgg	ttttttgatt	tttagtttga	ttttattatg	10140
atttttatta	tattatttttt	tttatatttt	taagaaagtt	tatatatttt	tttttttttt	10200
ttaaaataat	tattttttata	ttatttttttt	ttttaaaatg	agtattttat	ataattgatg	10260
tttaataaaa	aaaatgaagt	aaaaaaatta	attttaatat	aatatgatat	ttttttttgt	10320
ttaagttatt	agtataatat	tttagtagaa	gttaaatatg	ttattgtttt	tttatgaata	10380
aaataaatgt	tagttatttg	aagtatatgt	ttacgatttt	taaattagta	atattaattt	10440
atttatttaa	tatgaggaaa	aggagtattg	attttttttt	tttttttttt	ttttgataaa	10500
ggattataat	tattaatttt	aagaaagaaa	aagataatag	ggaatttttt	gtagtatat	10560
gttttatatt	atgataaata	taattttaat	tttgatatatt	ttttgtggtt	taataataagg	10620
aaatatgtga	gttgattttat	tttatagtta	ttttgattat	aaatggtata	tttttgaaaa	10680
ttatattaat	ttttattgat	ttttaagtga	ttattaatta	ttgtttagat	tttttttatt	10740
ttattaaata	ttttattaaa	tattgatatt	tttttgagt	aatgttaa	agaaaagttg	10800
gataaatata	tttttggggt	tttggggaga	gtgaagtggg	taaatttggg	gagttatttt	10860
ttttaaattt	tattattata	atgtattatt	attaattatt	ttatataatt	atataatatt	10920
tgattttttt	ataaaaattt	ttataaata	ttattatgtt	taatttttat	aatttttatta	10980
gagtagattt	tatttttaaat	aggaattttt	ttaaaagttt	tatttagtta	gtaagagatt	11040
gttttttgg	ttttatttat	tgtaaaaatt	ttgtgtgttt	tatatgttta	aaatttagat	11100
ttagataata	aggaggtagg	taggatttag	taggagtaga	gagaaatagg	agaatttaga	11160
atagagtttt	gaggaagaaa	gttgattttt	tattgggtaa	agtattgatt	ataaggaaaa	11220
ttggaaatga	acgtaaaaat	tgttggtttt	aaaatatatt	tatttattta	atttttttat	11280
tttagaaata	tttataaaga	atttagtatg	tgttaggttt	aggagatatg	atgaattatt	11340
aaatgtagta	gatttatatt	tagtttggtta	attttatagg	aattttattt	tgttttgttt	11400
tgtttttgtt	tttttgagat	agaattttat	tgtgttgttt	aggttggagt	gtagtggcgt	11460
aatttttagt	tattgtaatt	tttgttttat	ggtttaagt	gtttttttgt	tttagttttt	11520
cgggtagttg	ggattatagg	tgtttattaa	tacgtttagt	taatttttgt	attttttgta	11580
gagacggggt	tttattacgt	tggttagggt	ggtttttaat	ttttgatttt	aagtgtatta	11640
tttgtttcgg	ttttttaaag	tgtaggatt	ataggcgtga	gttattatat	ttgttttaga	11700
attttatttt	ttatttaatt	aagtaataag	ttataagaat	ttaatatatt	tttggtatcg	11760
ttggtggaat	gttatggttt	gaatgtttgt	gtacgtttta	aatttatatt	ttgaaatttt	11820
aatttataat	gtgatggtat	taggaggtgg	ttagattaag	tgattgtaga	gagtttagtag	11880
ttttttttat	tatgtgggga	tatagagagt	aggtattatt	tatgaataag	ggaatagggt	11940
tttattagat	attaaatttg	ttagtattac	gtttttgaat	tttttagttt	ttagaattgt	12000
gagaaataaa	tttttgtttg	ttatagttat	ttaggttata	gtatttttgt	atagtagttt	12060
taataaaatta	agatatgggg	ttatatagtt	aaataatttt	tggttttggt	tattgttatt	12120
aggaagttta	tagtttcgta	cgggagatta	gatatttaat	gaagtgaaaa	gagtggtaaa	12180
gaaggatat	aggagttata	gagatagtat	ataggagaga	gggacgagtt	ttatttaagt	12240
gggtgttgg	aggggttggt	tttttagtga	ggttttaaa	acgcgtggga	atttgtaagt	12300
taggcgagat	aggttaggat	attttaagt	gaagaaatag	gatgtttaga	agcgttaagt	12360
tgtagaagaa	tatgatgtgt	tttaggggaa	ggggaagtta	tttagaatag	aggaaatttg	12420
gggtgttagg	tagaggggtg	gtattgttat	ttttttagg	ttaggtttat	ggatagatta	12480
agttagggtta	agaattattt	taaatttgg	taggtatgat	ggtttatgtt	tataatttta	12540
gtgttttgag	aagttgagga	gggaggatta	ggagtttgag	attagtttgg	ataatatagt	12600
aagattttgt	ttttataaaa	aaagtaaaaa	taaagaaata	ttttaaattt	tatttgttat	12660
ggatatgtga	aaataaggtg	taggggtttt	tggagttagt	agataaatta	ttaaggaatt	12720
gatttatttt	ggtgaaggtg	gatttaattt	tttttaagag	aatattaggt	taggtgtagt	12780
ggtttatgtt	tgtaatttta	gtattttggg	aggtcgaggc	gggtggatta	tttgaggtta	12840
ggagtttgag	attagtttgg	ttaatatagt	gaaattttgt	tgttattaaa	aatttaaaaa	12900
aaattagttag	gtatggtggc	gggtatttgt	aatttttagt	attgggaggt	tgaggtagga	12960
gtattgtttg	aatttaggag	gtggaggttg	tagtgagtta	agattgtgtt	attgtatttt	13020
agtttgggag	atagagtaag	attttattta	aaaaaaaaaa	aaaaaaaaaa	aaaaaagaga	13080
atattattaa	ttggcggtat	tttttatgtt	tttattatta	aggttttagaa	tta	13133

**HUMANIZED FcγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE
THEREOF**

This application claims the benefit of U.S. Provisional Application No. 60/582,043, filed on June 21, 2004, and U.S. Provisional Application No. 60/569,882, filed May 10, 2004, each of which is incorporated herein by reference in its entirety.

1. FIELD OF THE INVENTION

[0001] The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer (preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma), autoimmune disease, inflammatory disease or IgE-mediated allergic disorder. The present invention also encompasses the use of a humanized FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention with a vaccine composition.

2. BACKGROUND OF THE INVENTION

2.1 Fc RECEPTORS AND THEIR ROLES IN THE IMMUNE SYSTEM

[0002] The interaction of antibody-antigen complexes with cells of the immune system results in a wide array of responses, ranging from effector functions such as antibody-dependent cytotoxicity, mast cell degranulation, and phagocytosis to immunomodulatory signals such as regulating lymphocyte proliferation and antibody secretion. All these interactions are initiated through the binding of the Fc domain of antibodies or immune complexes to specialized cell surface receptors on hematopoietic cells. The diversity of cellular responses triggered by antibodies and immune complexes results from the structural heterogeneity of Fc receptors. Fc receptors share structurally related ligand binding domains which presumably mediate intracellular signaling.

[0003] The Fc receptors, members of the immunoglobulin gene superfamily of proteins, are surface glycoproteins that can bind the Fc portion of immunoglobulin molecules.

Each member of the family recognizes immunoglobulins of one or more isotypes through a recognition domain on the α chain of the Fc receptor. Fc receptors are defined by their specificity for immunoglobulin subtypes. Fc receptors for IgG are referred to as Fc γ R, for IgE as Fc ϵ R, and for IgA as Fc α R. Different accessory cells bear Fc receptors for antibodies of different isotype, and the isotype of the antibody determines which accessory cells will be engaged in a given response (reviewed by Ravetch J.V. *et al.* 1991, *Annu. Rev. Immunol.* 9: 457-92; Gerber J.S. *et al.* 2001 *Microbes and Infection*, 3: 131-139; Billadeau D.D. *et al.* 2002, *The Journal of Clinical Investigation*, 2(109): 161-168; Ravetch J.V. *et al.* 2000, *Science*, 290: 84-89; Ravetch J.V. *et al.*, 2001 *Annu. Rev. Immunol.* 19:275-90; Ravetch J.V. 1994, *Cell*, 78(4): 553-60). The different Fc receptors, the cells that express them, and their isotype specificity is summarized in Table 1 (adapted from Immunobiology: The Immune System in Health and Disease, 4th ed. 1999, Elsevier Science Ltd/Garland Publishing, New York).

Fc γ Receptors

[0004] Each member of this family is an integral membrane glycoprotein, possessing extracellular domains related to a C2-set of immunoglobulin-related domains, a single membrane spanning domain and an intracytoplasmic domain of variable length. There are three known Fc γ Rs, designated Fc γ RI(CD64), Fc γ RII(CD32), and Fc γ RIII(CD16). The three receptors are encoded by distinct genes; however, the extensive homology between the three family members suggest they arose from a common progenitor perhaps by gene duplication. This invention specifically focuses on Fc γ RII(CD32).

Fc γ RII(CD32)

[0005] Fc γ RII proteins are 40KDa integral membrane glycoproteins which bind only the complexed IgG due to a low affinity for monomeric Ig (10^6 M⁻¹). This receptor is the most widely expressed Fc γ R, present on all hematopoietic cells, including monocytes, macrophages, B cells, NK cells, neutrophils, mast cells, and platelets. Fc γ RII has only two immunoglobulin-like regions in its immunoglobulin binding chain and hence a much lower affinity for IgG than Fc γ RI. There are three human Fc γ RII genes (Fc γ RII-A, Fc γ RII-B, Fc γ RII-C), all of which bind IgG in aggregates or immune complexes.

[0006] Distinct differences within the cytoplasmic domains of Fc γ RII-A (CD32A) and Fc γ RII-B (CD32B) create two functionally heterogenous responses to receptor ligation. The fundamental difference is that the A isoform initiates intracellular signaling leading to cell activation such as phagocytosis and respiratory burst, whereas the B isoform initiates inhibitory signals, e.g., inhibiting B-cell activation.

Signaling through FcγRs

[0007] Both activating and inhibitory signals are transduced through the FcγRs following ligation. These diametrically opposing functions result from structural differences among the different receptor isoforms. Two distinct domains within the cytoplasmic signaling domains of the receptor called immunoreceptor tyrosine based activation motifs (ITAMs) or immunoreceptor tyrosine based inhibitory motifs (ITIMs) account for the different responses. The recruitment of different cytoplasmic enzymes to these structures dictates the outcome of the FcγR-mediated cellular responses. ITAM-containing FcγR complexes include FcγRI, FcγRIIA, FcγRIIA, whereas ITIM-containing complexes only include FcγRIIB.

[0008] Human neutrophils express the FcγRIIA gene. FcγRIIA clustering via immune complexes or specific antibody cross-linking serves to aggregate ITAMs along with receptor-associated kinases which facilitate ITAM phosphorylation. ITAM phosphorylation serves as a docking site for Syk kinase, activation of which results in activation of downstream substrates (*e.g.*, PI₃K). Cellular activation leads to release of proinflammatory mediators.

[0009] The FcγRIIB gene is expressed on B lymphocytes; its extracellular domain is 96% identical to FcγRIIA and binds IgG complexes in an indistinguishable manner. The presence of an ITIM in the cytoplasmic domain of FcγRIIB defines this inhibitory subclass of FcγR. Recently the molecular basis of this inhibition was established. When co-ligated along with an activating FcγR, the ITIM in FcγRIIB becomes phosphorylated and attracts the SH2 domain of the inositol polyphosphate 5'-phosphatase (SHIP), which hydrolyzes phosphoinositol messengers released as a consequence of ITAM-containing FcγR-mediated tyrosine kinase activation, consequently preventing the influx of intracellular Ca⁺⁺. Thus, crosslinking of FcγRIIB dampens the activating response to FcγR ligation and inhibits cellular responsiveness. B cell activation, B cell proliferation and antibody secretion is thus aborted.

TABLE 1. Receptors for the Fc Regions of Immunoglobulin Isotypes

Receptor	FcγRI (CD64)	FcγRII-A (CD32)	FcγRII-B2 (CD32)	FcγRII-B1 (CD32)	FcγRIII (CD16)	FcεRI	FcαRI (CD89)
Binding	IgG1 10^8 M^{-1}	IgG1 $2 \times 10^6 \text{ M}^{-1}$	IgG1 $2 \times 10^6 \text{ M}^{-1}$	IgG1 $2 \times 10^6 \text{ M}^{-1}$	IgG1 $5 \times 10^5 \text{ M}^{-1}$	IgG1 10^{10} M^{-1}	IgG1, IgA2 10^7 M^{-1}
Cell Type	Macrophages Neutrophils Eosinophils Dendritic cells	Macrophages Neutrophils Eosinophils Dendritic cells Platelets Langerhan cells	Macrophages Neutrophils Eosinophils	B cells Mast cells	NK cells Eosinophil macrophages Neutrophils Mast Cells	Mast cells Eosinophil Basophils	Macrophages Neutrophils Eosinophils
Effect of Ligation	Uptake Stimulation Activation of respiratory burst Induction of killing	Uptake Granule release	Uptake Inhibition of Stimulation	No uptake Inhibition of Stimulation	Induction of Killing	Secretion of granules	Uptake Induction of killing

2.2 DISEASES OF RELEVANCE

2.2.1 CANCER

[0010] A neoplasm, or tumor, is a neoplastic mass resulting from abnormal uncontrolled cell growth which can be benign or malignant. Benign tumors generally remain localized. Malignant tumors are collectively termed cancers. The term "malignant" generally means that the tumor can invade and destroy neighboring body structures and spread to distant sites to cause death (for review, see Robbins and Angell, 1976, *Basic Pathology*, 2d Ed., W.B. Saunders Co., Philadelphia, pp. 68-122). Cancer can arise in many sites of the body and behave differently depending upon its origin. Cancerous cells destroy the part of the body in which they originate and then spread to other part(s) of the body where they start new growth and cause more destruction.

[0011] More than 1.2 million Americans develop cancer each year. Cancer is the second leading cause of death in the United States and if current trends continue, cancer is expected to be the leading cause of the death by the year 2010. Lung and prostate cancer are the top cancer killers for men in the United States. Lung and breast cancer are the top cancer killers for women in the United States. One in two men in the United States will be diagnosed with cancer at some time during his lifetime. One in three women in the United States will be diagnosed with cancer at some time during her lifetime.

[0012] A cure for cancer has yet to be found. Current treatment options, such as surgery, chemotherapy and radiation treatment, are oftentimes either ineffective or present serious side effects.

2.2.1.1 B-CELL MALIGNANCIES

[0013] B cell malignancies, including, but not limited to, B-cell lymphomas and leukemias, are neoplastic diseases with significant incidence in the United States. There are approximately 55,000 new lymphoma cases of per year in the U.S. (1998 data), with an estimated 25,000 deaths per year. This represents 4% of cancer incidence and 4% of all cancer-related deaths in the U.S. population. The revised European-American classification of lymphoid neoplasms (1994 REAL classification, modified 1999) grouped lymphomas based on their origin as either B cell lineage lymphoma, T cell lineage lymphoma, or Hodgkin's lymphoma. Lymphoma of the B cell lineage is the most common type of non-Hodgkin's lymphoma (NHL) diagnosed in the U.S. (Williams, Hematology 6th ed. (Beutler et al. Ed.), McGraw Hill 2001).

[0014] Chronic lymphocytic leukemia (CLL) is a neoplastic disease characterized by the accumulation of small, mature-appearing lymphocytes in the blood, marrow, and lymphoid

tissues. CLL has an incidence of 2.7 cases per 100,000 in the U.S. The risk increases progressively with age, particularly in men. It accounts for 0.8% of all cancers and is the most common adult leukemia, responsible for 30% of all leukemias. In nearly all cases (>98%) the diseased cells belong to the B lymphocyte lineage. A non-leukemic variant, small lymphocytic lymphoma, constitutes 5-10% of all lymphomas, has histological, morphological and immunological features indistinguishable from that of involved lymph nodes in patients with B-CLL (Williams, 2001).

[0015] The natural history of chronic lymphocytic leukemia falls into several phases. In the early phase, chronic lymphocytic leukemia is an indolent disease, characterized by the accumulation of small, mature, functionally-incompetent malignant B-cells having a lengthened life span. Eventually, the doubling time of the malignant B-cells decreases and patients become increasingly symptomatic. While treatment with chemotherapeutic agents can provide symptomatic relief, the overall survival of the patients is only minimally extended. The late stages of chronic lymphocytic leukemia are characterized by significant anemia and/or thrombocytopenia. At this point, the median survival is less than two years (Foon et al., 1990, *Annals Int. Medicine* 113:525). Due to the very low rate of cellular proliferation, chronic lymphocytic leukemia is resistant to treatment with chemotherapeutic agents.

[0016] Recently, gene expression studies have identified several genes that may be up regulated in lymphoproliferative disorders. One molecule thought to be over-expressed in patients with B-cell chronic lymphocytic leukemia (B-CLL) and in a large fraction of non-Hodgkin lymphoma patients is CD32B (Alizadeh et al., 2000, *Nature* 403:503-511; Rosenwald et al., 2001, *J. Exp. Med.* 184:1639-1647). However, the role of CD32B in B-CLL is unclear since one report demonstrates that CD32B was expressed on a low percentage of B-CLL cells and at a low density (Damle et al., 2002, *Blood* 99:4087-4093). CD32B is a B cell lineage surface antigen, whose over-expression in B cell neoplasia makes it a suitable target for therapeutic antibodies. In addition, CD32B belongs to the category of inhibitory receptors, whose ligation delivers a negative signal. Therefore, antibodies directed against CD32B could function to eliminate tumor cells by mechanisms that include complement dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), but also triggering an apoptotic signal. The high homology of CD32B with its counterpart, CD32A, an activating Fc γ receptor, has thus far hampered the generation of antibodies that selectively recognize one but not the other form of the molecule.

2.2.1.2 Cancer Therapy

[0017] Currently, cancer therapy may involve surgery, chemotherapy, hormonal therapy and/or radiation treatment to eradicate neoplastic cells in a patient (*See*, for example,

Stockdale, 1998, "Principles of Cancer Patient Management", in Scientific American: Medicine, vol. 3, Rubenstein and Federman, eds., Chapter 12, Section IV). Cancer therapy can also involve biological therapy or immunotherapy. All of these approaches pose significant drawbacks for the patient. Surgery, for example, may be contraindicated due to the health of the patient or may be unacceptable to the patient. Additionally, surgery may not completely remove the neoplastic tissue. Radiation therapy is only effective when the neoplastic tissue exhibits a higher sensitivity to radiation than normal tissue, and radiation therapy can also often elicit serious side effects. Hormonal therapy is rarely given as a single agent and, although it can be effective alone, is often used to prevent or delay recurrence of cancer after other treatments have removed the majority of the cancer cells. Biological therapies/immunotherapies are limited in number and may produce side effects such as rashes or swellings, flu-like symptoms, including fever, chills and fatigue, digestive tract problems or allergic reactions.

[0018] With respect to chemotherapy, there are a variety of chemotherapeutic agents available for treatment of cancer. A significant majority of cancer chemotherapeutics act by inhibiting DNA synthesis, either directly, or indirectly by inhibiting the biosynthesis of the deoxyribonucleotide triphosphate precursors, to prevent DNA replication and concomitant cell division (*See, for example, Gilman et al., Goodman and Gilman's: The Pharmacological Basis of Therapeutics, Eighth Ed. (Pergamom Press, New York, 1990)*). These agents, which include alkylating agents, such as nitrosourea, anti-metabolites, such as methotrexate and hydroxyurea, and other agents, such as etoposides, campathecins, bleomycin, doxorubicin, daunorubicin, *etc.*, although not necessarily cell cycle specific, kill cells during S phase because of their effect on DNA replication. Other agents, specifically colchicine and the vinca alkaloids, such as vinblastine and vincristine, interfere with microtubule assembly resulting in mitotic arrest. Chemotherapy protocols generally involve administration of a combination of chemotherapeutic agents to increase the efficacy of treatment.

[0019] Despite the availability of a variety of chemotherapeutic agents, chemotherapy has many drawbacks (*See, for example, Stockdale, 1998, "Principles Of Cancer Patient Management" in Scientific American Medicine, vol. 3, Rubenstein and Federman, eds., ch. 12, sect. 10*). Almost all chemotherapeutic agents are toxic, and chemotherapy causes significant, and often dangerous, side effects, including severe nausea, bone marrow depression, immunosuppression, *etc.* Additionally, even with administration of combinations of chemotherapeutic agents, many tumor cells are resistant or develop resistance to the chemotherapeutic agents. In fact, those cells resistant to the particular chemotherapeutic agents used in the treatment protocol often prove to be resistant to other drugs, even those

agents that act by mechanisms different from the mechanisms of action of the drugs used in the specific treatment; this phenomenon is termed pleiotropic drug or multidrug resistance. Thus, because of drug resistance, many cancers prove refractory to standard chemotherapeutic treatment protocols.

[0020] B cell malignancy is generally treated with single agent chemotherapy, combination chemotherapy and/or radiation therapy. These treatments can reduce morbidity and/or improve survival, albeit they carry significant side effects. The response of B-cell malignancies to various forms of treatment is mixed. For example, in cases in which adequate clinical staging of non-Hodgkin's lymphoma is possible, field radiation therapy can provide satisfactory treatment. Certain patients, however, fail to respond and disease recurrence with resistance to treatment ensues with time, particularly with the most aggressive variants of the disease. About one-half of the patients die from the disease (Devesa et al., 1987, *J. Nat'l Cancer Inst.* 79:701).

[0021] Investigational therapies for the treatment of refractory B cell neoplasia include autologous and allogeneic bone marrow or stem cell transplantation and gene therapies. Recently, immunotherapy using monoclonal antibodies to target B-cell specific antigens has been introduced in the treatment of B cell neoplasia. The use of monoclonal antibodies to direct radionuclides, toxins, or other therapeutic agents offers the possibility that such agents can be delivered selectively to tumor sites, thus limiting toxicity to normal tissues.

[0022] There is a significant need for alternative cancer treatments, particularly for treatment of cancer that has proved refractory to standard cancer treatments, such as surgery, radiation therapy, chemotherapy, and hormonal therapy. A promising alternative is immunotherapy, in which cancer cells are specifically targeted by cancer antigen-specific antibodies. Major efforts have been directed at harnessing the specificity of the immune response, for example, hybridoma technology has enabled the development of tumor selective monoclonal antibodies (See Green M.C. et al., 2000 *Cancer Treat Rev.*, 26: 269-286; Weiner LM, 1999 *Semin Oncol.* 26(suppl. 14):43-51), and in the past few years, the Food and Drug Administration has approved the first MAb for cancer therapy: Rituxan (anti-CD20) for non-Hodgkin's Lymphoma, Campath (anti-CD52) for B-cell chronic lymphocytic leukemia (B-CLL) and Herceptin [anti-(c-erb-2/HER-2)] for metastatic breast cancer (Suzanne A. Eccles, 2001, *Breast Cancer Res.* 3: 86-90). NHL and B-CLL are two of the most common forms of B cell neoplasia. These antibodies have demonstrated clinical efficacy, but their use is not without side effects. The potency of antibody effector function, e.g., to mediate antibody dependent cellular cytotoxicity ("ADCC") is an obstacle to such treatment. Furthermore, with

Rituxan and Campath, at least half the patients fail to respond and a fraction of responders may be refractory to subsequent treatments.

[0023] There is a need for alternative therapies for cancer, particularly, B-cell malignancies, especially for patients that are refractory for standard cancer treatments and new immunotherapies such as Rituxan.

2.2.2 INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES

[0024] Inflammation is a process by which the body's white blood cells and chemicals protect our bodies from infection by foreign substances, such as bacteria and viruses. It is usually characterized by pain, swelling, warmth and redness of the affected area. Chemicals known as cytokines and prostaglandins control this process, and are released in an ordered and self-limiting cascade into the blood or affected tissues. This release of chemicals increases the blood flow to the area of injury or infection, and may result in the redness and warmth. Some of the chemicals cause a leak of fluid into the tissues, resulting in swelling. This protective process may stimulate nerves and cause pain. These changes, when occurring for a limited period in the relevant area, work to the benefit of the body.

[0025] In autoimmune and/or inflammatory disorders, the immune system triggers an inflammatory response when there are no foreign substances to fight and the body's normally protective immune system causes damage to its own tissues by mistakenly attacking itself. There are many different autoimmune disorders which affect the body in different ways. For example, the brain is affected in individuals with multiple sclerosis, the gut is affected in individuals with Crohn's disease, and the synovium, bone and cartilage of various joints are affected in individuals with rheumatoid arthritis. As autoimmune disorders progress, destruction of one or more types of body tissues, abnormal growth of an organ, or changes in organ function may result. The autoimmune disorder may affect only one organ or tissue type or may affect multiple organs and tissues. Organs and tissues commonly affected by autoimmune disorders include red blood cells, blood vessels, connective tissues, endocrine glands (e.g., the thyroid or pancreas), muscles, joints, and skin. Examples of autoimmune disorders include, but are not limited to, Hashimoto's thyroiditis, pernicious anemia, Addison's disease, type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, Sjogren's syndrome, multiple sclerosis, autoimmune inner ear disease, inflammatory bowel disease, arthritis, myasthenia gravis, Reiter's syndrome, Graves disease, autoimmune hepatitis, familial adenomatous polyposis and ulcerative colitis.

[0026] Rheumatoid arthritis (RA) and juvenile rheumatoid arthritis are types of inflammatory arthritis. Arthritis is a general term that describes inflammation in joints. Some,

but not all, types of arthritis are the result of misdirected inflammation. Besides rheumatoid arthritis, other types of arthritis associated with inflammation include the following: psoriatic arthritis, Reiter's syndrome, ankylosing spondylitis arthritis, and gouty arthritis. Rheumatoid arthritis is a type of chronic arthritis that occurs in joints on both sides of the body (such as both hands, wrists or knees). This symmetry helps distinguish rheumatoid arthritis from other types of arthritis. In addition to affecting the joints, rheumatoid arthritis may occasionally affect the skin, eyes, lungs, heart, blood or nerves.

[0027] Rheumatoid arthritis affects about 1% of the world's population and is potentially disabling. There are approximately 2.9 million incidences of rheumatoid arthritis in the United States. Two to three times more women are affected than men. The typical age that rheumatoid arthritis occurs is between 25 and 50. Juvenile rheumatoid arthritis affects 71,000 young Americans (aged eighteen and under), affecting six times as many girls as boys.

[0028] Rheumatoid arthritis is an autoimmune disorder where the body's immune system improperly identifies the synovial membranes that secrete the lubricating fluid in the joints as foreign. Inflammation results, and the cartilage and tissues in and around the joints are damaged or destroyed. In severe cases, this inflammation extends to other joint tissues and surrounding cartilage, where it may erode or destroy bone and cartilage and lead to joint deformities. The body replaces damaged tissue with scar tissue, causing the normal spaces within the joints to become narrow and the bones to fuse together. Rheumatoid arthritis creates stiffness, swelling, fatigue, anemia, weight loss, fever, and often, crippling pain. Some common symptoms of rheumatoid arthritis include joint stiffness upon awakening that lasts an hour or longer; swelling in a specific finger or wrist joints; swelling in the soft tissue around the joints; and swelling on both sides of the joint. Swelling can occur with or without pain, and can worsen progressively or remain the same for years before progressing.

[0029] The diagnosis of rheumatoid arthritis is based on a combination of factors, including: the specific location and symmetry of painful joints, the presence of joint stiffness in the morning, the presence of bumps and nodules under the skin (rheumatoid nodules), results of X-ray tests that suggest rheumatoid arthritis, and/or positive results of a blood test called the rheumatoid factor. Many, but not all, people with rheumatoid arthritis have the rheumatoid-factor antibody in their blood. The rheumatoid factor may be present in people who do not have rheumatoid arthritis. Other diseases can also cause the rheumatoid factor to be produced in the blood. That is why the diagnosis of rheumatoid arthritis is based on a combination of several factors and not just the presence of the rheumatoid factor in the blood.

[0030] The typical course of the disease is one of persistent but fluctuating joint symptoms, and after about 10 years, 90% of sufferers will show structural damage to bone and

cartilage. A small percentage will have a short illness that clears up completely, and another small percentage will have very severe disease with many joint deformities, and occasionally other manifestations of the disease. The inflammatory process causes erosion or destruction of bone and cartilage in the joints. In rheumatoid arthritis, there is an autoimmune cycle of persistent antigen presentation, T-cell stimulation, cytokine secretion, synovial cell activation, and joint destruction. The disease has a major impact on both the individual and society, causing significant pain, impaired function and disability, as well as costing millions of dollars in healthcare expenses and lost wages (*see, for example, the NIH website and the NIAID website*).

[0031] Currently available therapy for arthritis focuses on reducing inflammation of the joints with anti-inflammatory or immunosuppressive medications. The first line of treatment of any arthritis is usually anti-inflammatories, such as aspirin, ibuprofen and Cox-2 inhibitors such as celecoxib and rofecoxib. "Second line drugs" include gold, methotrexate and steroids. Although these are well-established treatments for arthritis, very few patients remit on these lines of treatment alone. Recent advances in the understanding of the pathogenesis of rheumatoid arthritis have led to the use of methotrexate in combination with antibodies to cytokines or recombinant soluble receptors. For example, recombinant soluble receptors and monoclonal antibodies for tumor necrosis factor (TNF)- α have been used in combination with methotrexate in the treatment of arthritis. However, only about 50% of the patients treated with a combination of methotrexate and anti-TNF- α agents such as recombinant soluble receptors for TNF- α show clinically significant improvement. Many patients remain refractory despite treatment. Difficult treatment issues still remain for patients with rheumatoid arthritis. Many current treatments have a high incidence of side effects or cannot completely prevent disease progression. So far, no treatment is ideal, and there is no cure. Novel therapeutics are needed that more effectively treat rheumatoid arthritis and other autoimmune disorders.

2.2.3 ALLERGY

[0032] Immune-mediated allergic (hypersensitivity) reactions are classified into four types (I-IV) according to the underlying mechanisms leading to the expression of the allergic symptoms. Type I allergic reactions are characterized by IgE-mediated release of vasoactive substances such as histamine from mast cells and basophils. The release of these substances and the subsequent manifestation of allergic symptoms are initiated by the cross-linking of allergen-bound IgE to its receptor on the surface of mast cells and basophils. In individuals suffering from type I allergic reactions, exposure to an allergen for a second time leads to the production of high levels of IgE antibodies specific for the allergen as a result of the involvement of memory B and T cells in the 3-cell interaction required for IgE production.

The high levels of IgE antibodies produced cause an increase in the cross-linking of IgE receptors on mast cells and basophils by allergen-bound IgE, which in turn leads to the activation of these cells and the release of the pharmacological mediators that are responsible for the clinical manifestations of type I allergic diseases.

[0033] Two receptors with differing affinities for IgE have been identified and characterized. The high affinity receptor (FcεRI) is expressed on the surface of mast cells and basophils. The low affinity receptor (FcεRII/CD23) is expressed on many cell types including B cells, T cells, macrophages, eosinophils and Langerhan cells. The high affinity IgE receptor consists of three subunits (alpha, beta and gamma chains). Several studies demonstrate that only the alpha chain is involved in the binding of IgE, whereas the beta and gamma chains (which are either transmembrane or cytoplasmic proteins) are required for signal transduction events. The identification of IgE structures required for IgE to bind to the FcεRI on mast cells and basophils is of utmost importance in devising strategies for treatment or prevention of IgE-mediated allergies. For example, the elucidation of the IgE receptor-binding site could lead to the identification of peptides or small molecules that block the binding of IgE to receptor-bearing cells *in vivo*.

[0034] Currently, IgE-mediated allergic reactions are treated with drugs such as antihistamines and corticosteroids which attempt to alleviate the symptoms associated with allergic reactions by counteracting the effects of the vasoactive substances released from mast cells and basophils. High doses of antihistamines and corticosteroids have deleterious side effects (*e.g.*, central nervous system disturbance, constipation, *etc*). Thus, other methods for treating type I allergic reactions are needed.

[0035] One approach to the treatment of type I allergic disorders has been the production of monoclonal antibodies which react with soluble (free) IgE in serum, block IgE from binding to its receptor on mast cells and basophils, and do not bind to receptor-bound IgE (*i.e.*, they are non-anaphylactogenic). One such antibody Xolair, has been approved by the FDA.

[0036] One of the most promising treatments for IgE-mediated allergic reactions is the active immunization against appropriate non-anaphylactogenic epitopes on endogenous IgE. Stanworth *et al.* (U.S. Patent No. 5,601,821) described a strategy involving the use of a peptide derived from the CεH4 domain of the human IgE coupled to a heterologous carrier protein as an allergy vaccine. However, this peptide has been shown not to induce the production of antibodies that react with native soluble IgE. Further, Hellman (U.S. Patent No. 5,653,980) proposed anti-IgE vaccine compositions based on fusion of full length CεH2-CεH3 domains (approximately 220 amino acid long) to a foreign carrier protein. However, the antibodies

induced by the anti-IgE vaccine compositions proposed in Hellman will most likely it result in anaphylaxis since antibodies against some portions of the CεH2 and CεH3 domains of the IgE molecule have been shown to cross-link the IgE receptor on the surface of mast cell and basophils and lead to production of mediators of anaphylaxis (*See, e.g., Stadler et al., 1993, Int. Arch. Allergy and Immunology* 102:121-126). Therefore, a need remains for treatment of IgE-mediated allergic reactions which do not induce anaphylactic antibodies.

[0037] The significant concern over induction of anaphylaxis has resulted in the development of another approach to the treatment of type I allergic disorders consisting of mimotopes that could induce the production of anti-IgE polyclonal antibodies when administered to animals (*See, e.g., Rudolf, et al., 1998, Journal of Immunology* 160:3315-3321). Krick *et al.* (International Publication No. WO 97/31948) screened phage-displayed peptide libraries with the monoclonal antibody BSWI7 to identify peptide mimotopes that could mimic the conformation of the IgE receptor binding. These mimotopes could presumably be used to induce polyclonal antibodies that react with free native IgE, but not with receptor-bound IgE as well as block IgE from binding to its receptor. Krick *et al.* disclosed peptide mimotopes that are not homologous to any part of the IgE molecule and are thus different from peptides disclosed in the present invention.

[0038] As evidenced by a survey of the art, there remains a need for enhancing the therapeutic efficacy of current methods of treating or preventing disorders such as cancer, autoimmune disease, inflammatory disorder, or allergy. In particular, there is a need for enhancing the effector function, particularly, the cytotoxic effect of therapeutic antibodies used in treatment of cancer. The current state of the art is also lacking in treating or preventing allergy disorders (*e.g., either by antibody therapy or vaccine therapy*).

3. SUMMARY OF THE INVENTION

[0039] The instant invention provides humanized FcγRIIB antibodies, an isolated antibody or a fragment thereof that specifically binds FcγRIIB, particularly human FcγRIIB, more particularly native human FcγRIIB, with a greater affinity than said antibody or a fragment thereof binds FcγRIIA, particularly human FcγRIIA, more particularly native human FcγRIIA. As used herein, "native FcγRIIB or FcγRIIA " means FcγRIIB or FcγRIIA which is endogenously expressed in a cell and is present on the cell surface of that cell or recombinantly expressed in a mammalian cell and present on the cell surface, but is not FcγRIIB or FcγRIIA expressed in a bacterial cell or denatured, isolated FcγRIIB or FcγRIIA. The instant invention encompasses humanized antibodies, and antigen binding fragments thereof, derived from antibodies that bind FcγRIIB, particularly human FcγRIIB, more particularly native human FcγRIIB, with a greater affinity than said antibody or a fragment thereof binds FcγRIIA,

CDR2 and a VL CDR3; a VH CDR1, a VH CDR2, a VH CDR3, a VL CDR1 and a VL CDR2; a VH CDR1, a VH CDR2, a VH CDR3, a VL CDR1 and a VL CDR3; a VH CDR1, a VH CDR2, a VL CDR1, a VL CDR2, and a VL CDR3; a VH CDR1, a VH CDR3, a VL CDR1, a VL CDR2, and a VL CDR3; a VH CDR2, a VH CDR3, a VL CDR1, a VL CDR2, and a VL CDR3; or any combination thereof of the VH CDRs and VL CDRs disclosed herein.

[0043] In one specific embodiment, the invention provides a humanized 2B6 antibody, wherein the VH region consists of the FR segments from the human germline VH segment VH1-18 and JH6, and the CDR regions of the 2B6 VH, having the amino acid sequence of SED ID NO. 24. In another specific embodiment, the humanized 2B6 antibody further comprises a VL regions, which consists of the FR segments of the human germline VL segment VK-A26 and JK4 and the CDR regions of 2B6VL, having an amino acid sequence of SEQ ID NO. 18, SEQ ID NO. 20, or SEQ ID NO. 22.

[0044] In one specific embodiment, the invention provides a humanized 3H7 antibody, wherein the VH region consists of the FR segments from a human germline VH segment, and the CDR regions of the 3H7 VH, having the amino acid sequence of SED ID NO. 37. In another specific embodiment, the humanized 3H7 antibody further comprises a VL regions, which consists of the FR segments of the human germline VL segment, and the CDR regions of 3H7VL, having an amino acid sequence of SEQ ID NO. 46.

[0045] The present invention provides humanized antibody molecules specific for FcγRIIB in which one or more regions of one or more CDRs of the heavy and/or light chain variable regions of a human antibody (the recipient antibody) have been substituted by analogous parts of one or more CDRs of a donor monoclonal antibody which specifically binds FcγRIIB, with a greater affinity than FcγRIIA, *e.g.*, monoclonal antibody produced by clones 2B6 and 3H7 which bind FcγRIIB, having ATCC accession numbers PTA-4591, and PTA-4592, respectively, or a monoclonal antibody produced by clones 1D5, 2E1, 2H9, 2D11, and 1F2 having ATCC Accession numbers, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively. In a most preferred embodiment, the humanized antibody can specifically bind to the same epitope as the donor murine antibody. It will be appreciated by one skilled in the art that the invention encompasses CDR grafting of antibodies in general. Thus, the donor and acceptor antibodies may be derived from animals of the same species and even same antibody class or sub-class. More usually, however, the donor and acceptor antibodies are derived from animals of different species. Typically the donor antibody is a non-human antibody, such as a rodent MAb, and the acceptor antibody is a human antibody.

[0046] In some embodiments, at least one CDR from the donor antibody is grafted onto the human antibody. In other embodiments, at least two and preferably all three CDRs of each

of the heavy and/or light chain variable regions are grafted onto the human antibody. The CDRs may comprise the Kabat CDRs, the structural loop CDRs or a combination thereof. In some embodiments, the invention encompasses a humanized FcγRIIB antibody comprising at least one CDR grafted heavy chain and at least one CDR-grafted light chain.

[0047] In a preferred embodiment, the CDR regions of the humanized FcγRIIB specific antibody are derived from the murine antibody against FcγRIIB. In some embodiments, the humanized antibodies described herein comprise alterations, including, but not limited to, amino acid deletions, insertions, and modifications, of the acceptor antibody, *i.e.*, human, heavy and/or light chain variable domain framework regions that are necessary for retaining binding specificity of the donor monoclonal antibody. In some embodiments, the framework regions of the humanized antibodies described herein do not necessarily consist of the precise amino acid sequence of the framework region of a natural occurring human antibody variable region, but contain various alterations, including, but not limited to, amino acid deletions, insertions, modifications that alter the property of the humanized antibody, for example.

10613524 seq id 74.txt

Sequence listing

<110> Epigenomics AG

<120> Diagnosis of Diseases Associated with
Signal Transduction

<160> 392

<210> 74

<211> 13133

<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<220>

<221> unsure

<222> (8922)

<400> 74

tttgggaattt	agataggaaa	tataaataga	aaagaagtgg	tgtttgttta	aatgggtgtat	60
aagtaatttt	taataatatt	atcgttttta	attttatatt	tataaaattt	tatttggttt	120
gagtaaaaagt	tataaaatat	gtgattttga	aaaatggatt	ttataaatgt	tatgtttaat	180
agataagatg	gtttgttgta	tatatattag	gttttttacg	gagatagaga	ttttaatttt	240
attatttttat	atttaaatatt	tagtatagg	tttggtatat	tatagggtgt	ttattttaatt	300
tatatttgat	ataaaaaatga	aataggatat	agaaaaaaat	atgtatatat	aagatttttat	360
gttggttttt	ttattttttag	attatagtat	tttttatatt	ttattttagta	gtttattaat	420
atgaagatag	ggattatggt	tgttttgttt	attatttttt	ttttaaatatt	tagagtttta	480
ttttgaaaat	atttttattat	tagtattttt	tttttttttg	aaaatttgat	gaaattttaag	540
tgtatatatg	attttagtgat	aaaaataaaa	attttgtggt	tttagatttg	aaagattttt	600
atgtagatgt	gtattatagt	attttatgaa	tttttgattt	atttttaaaa	gttttttaggt	660
tttattaatt	gtaataattta	tttaagggtat	ttagtttta	aaatttaagta	acgattatat	720
tgtttggttt	tttttcggag	gggttagtg	tttagttttt	tgaagatggt	tatttttata	780
agttgttggg	atattttagat	ttttaaatag	gaattttaag	aagtaatttt	tgtttttaggt	840
atgtatgta	tttttgaata	tttttgttta	aattttatta	atgggtgtgaa	tttaagggtat	900
ttagtttttt	attgagaatt	tttttgggat	tttttttaag	tattatgggt	gttgagagggt	960
aaggggtagg	agaggattgg	tagttaggat	ttttttttag	ttaggaattt	ttgttttgga	1020
tttaatttttag	ttttaaaagta	gtttggtagg	tgatttttgt	atgaaatttt	atattatttt	1080
gttattataa	tttattttat	ttagttaatt	ggtattaata	gaaggttggt	tgttaaagt	1140
atagagtttt	tgtttttttag	gaattttata	tttaatttag	gaagtttatt	gttattagta	1200
ttttttttat	tatttttttt	ttaatttttt	ttttggggtt	ttatatatta	ttgaaagagt	1260
agaagggttt	tgtatatgta	atataagta	ttaaaatatg	atgttggaat	atgttgatta	1320
taaaatgaaa	ttttaatttt	tttttattag	tagattaaga	cgtttatatt	ttttttattg	1380
gatataata	atgtataatg	attatgtgga	gtgtgagttt	tttttttggt	tattttta	1440
taaaataaaa	tagaagataa	tatttggggt	ttgtttgatt	gtgattttat	aggtttaggg	1500
atattatttt	ttagatttat	aaattgagtt	ttttattata	tttatagatg	atattttatg	1560
ttagggtgatt	ttatatttaa	taagagtagt	tagaaagggt	atttttattt	tgttttatgt	1620
taaaagtagg	gtagtttata	aaaatgaatt	aggtaagttt	tgggtatata	taaaagagggt	1680
atagggttgt	ttaatgtttt	tttttttttag	tttcgttttt	tgtatttttt	tttgttttatt	1740
gtgggttttt	aaatattaga	taataaaagga	gtttgaattta	aaatattttt	tttttataga	1800
attatttttt	ttagagtggg	gtggtgat	tttagtagaa	aaatttatat	tatttgtata	1860
tatgtttata	aaagtataaa	gtttttttatt	aggataaaa	taattttggg	gttttagaga	1920
tttttaaaaa	tatagtaaag	taaaattaa	tttttagaaat	ttatttttaag	taatttttgt	1980
gtttcgtata	atttaatat	tgattataaa	tgtttttagta	attaaaatta	acgagattga	2040
taagaaacga	ttatttttta	tattttta	tggttttttt	tgtagtatta	2100	
attattattt	aattttaggt	ggatttaaga	gttttttagg	gttttaattt	cgattttttt	2160
ggttttttat	ttttataatt	ttttgtaatt	gattttgaa	atagtttagg	tttttagta	2220
tgtttatggt	ttgatgtttg	cgtatttggt	ttttgagttt	agatttttta	aggtgtttat	2280
ttttgagtggt	aagatatata	tatttaatta	tcgattagtt	ttttttttta	taagtaattt	2340

10613524 seq id 74.txt

aaatttaatt	tatgattttt	ttaataaatt	agttttttat	ttttataatt	ttttattttt	2400
gataaaaaga	agggtttttt	tttatgtgtt	attttaggtta	tttttttgcg	aatgaatttt	2460
tagtattgtg	tgtttgga	attttaatat	ttttttttat	tttttaagtt	attaagaaga	2520
tgtattatta	ttattttagg	ttttttttat	taatattggt	ttattttatt	tttttgatgt	2580
tttttattgg	gataattgag	gtagtatcgt	aatatgtttt	tttgttttta	agtttagaat	2640
tttttaaatt	ttttttttat	agtgttttta	gagtttgatt	taaaagtttt	aatttgagat	2700
tatttttgtt	tttgtttaag	gtttgtgggt	gtaattttat	tttatagtta	atgtaagaat	2760
ttattagtaa	gaatataagg	ttttaaaatg	tagaggttta	atgatcggag	tttttttatt	2820
tttattaatt	attgttattt	ttttttttta	gagaataaag	ttagatagtt	taggatttaa	2880
aaaatattat	atattttttat	atttttttgt	tttttagtgag	gttaggtttt	ataatggtag	2940
attttttagtt	agatatatat	taaatgattt	agtttttatta	tttattaaat	gtgtgattta	3000
gggtaattta	ttttattttt	gttaattttta	gtgtttttgt	ttgtaaaaag	aaggtaataa	3060
agttatttta	ttaggggtttt	tagggggatt	aaataaggta	atatgtgtaa	agtgtttagt	3120
agtttagttta	tgagagtagt	attattgttt	tttttagata	ttttttgtta	tttttttttt	3180
tatatttagg	tgattttatt	ttttttttat	ttttttttat	tgtaattgtt	ttaatattag	3240
atgtatttat	ttgggtgtga	gtaatttttag	ggttgggttt	ttttttatgt	ttttaagttt	3300
ttattaatat	aaatttaggt	atatagtaag	tttttaataa	atatttttgg	gatggaagaa	3360
tatatgttaa	tagatttttt	ttgttaattt	ttgttttttt	tggagttgtt	tttgagaatt	3420
atattgtgta	tttttataag	gaaatatgaa	gttaagggtt	aggggaattta	gaaacgtttt	3480
tggtgattta	agttataaga	cgttaggttt	gtagtggatt	cgtatagatt	tggaggttaa	3540
ggatttttta	gtataaagta	tttgtagtag	atatattaat	taaattatgt	ataaaatttt	3600
tgtaataaat	atattaatta	aatatttttaa	agtaatatat	gtaattttta	aagtttttta	3660
gatgttagag	atttatttga	gaagtttttag	taaaagaaga	ttttgaattt	taaatattgt	3720
aggattttta	aattataatt	aagttttaaa	gtataattaa	ttgattttata	aaaaatgggg	3780
tagagagtag	ggtgggggtg	ttgagggatt	agaaatgtta	gaatattttt	agaatacgtta	3840
tgtaagatt	atatttataaa	tttaaggata	ttaaaaattt	tttttttttag	tttagttttt	3900
tgaagtttga	gattatgggt	tatttcgata	tgtaaatgta	tagtatagtg	tgtgttatat	3960
ttaaaaatat	atattgaggt	cgggtatagg	ggtttaattt	tgtaatttta	gtattttggg	4020
aggttgaggt	agggtggatta	tttgaggtta	ggagttttata	attaatttgg	ttaatatggt	4080
gaaattttat	ttttatttaa	aatataaaaa	ttagtttaggt	atgggtggcgg	gtgtttgtta	4140
tttttagttat	ttgggtgggt	aaggtaagag	aatcgtttga	atttcggagg	cggaggttgt	4200
agtgagtcga	gatggagtta	ttgtatttta	gtttgggtta	tagagtgaga	tttcgtttta	4260
aaaaaataaa	ataaaataaa	ataaaaaata	aaaaataaat	ataattgtta	aaatagttat	4320
aatttatggg	ttcgaattga	gagatttgta	aaggtttttt	tgattattaa	gtattttggt	4380
attaaatatt	atataaaaaat	aatagtttaa	ttagtttggt	agttttttatt	ttttttaata	4440
agaaaaatgg	aaatagtaga	tattttattg	tgataatagt	tttgggcgtt	taaaaatttt	4500
tttgaaagtt	ttttagaaat	gttgatatagt	attatggtaa	tagaattgag	tttaaaaaaga	4560
ttggaatttt	agtttttttt	taaaattttt	gatagttttg	gtgggtttgt	tagaaagaaa	4620
aatgtttatt	tttttttttt	taaaatattg	ttattttttta	aaatgtgtat	tttaatttga	4680
attattttat	aaaggtaaaa	ttgataattg	gagtgtttta	tatagtaaaa	tagttataaa	4740
agttatatat	attttaatat	ttttgaattt	aaaaatattt	ttattaataa	ttattaatta	4800
atattaatag	aaaaataata	ggaagtaaga	tagtgattgg	gtatatattt	tttttttata	4860
taaatagaaa	taattaaagt	gtaaaataat	ttatatatgg	agatataaaa	taaaagggtta	4920
atggtttaga	taaattttta	agtttataat	ttttataatt	atataattta	tttgttttat	4980
Datattatttg	taagagaaaa	tgtgggtaag	tttttatgat	aagattattt	ttattttttt	5040
aatgtttttt	cgtttttttat	ttatttttaga	agtttttttt	aggtgtaatt	attttgga	5100
taataattaa	aaatttataa	aaatttgata	gatatatggg	aatatggatt	tataaagggt	5160
tttgatttta	taatgagggt	agtataattt	tttagaatta	gtagttttta	ttagtattat	5220
aaaattagat	gtaggaggat	gtaggttttt	attttggttt	tgatatgaat	tgggtgggga	5280
attttgatga	aaattgtttat	ttcgttttag	tattgttttt	tattttataa	ttgaaagaat	5340
agaattagat	aaatttttgg	gtttttgtta	ttttttttgt	attatgaaat	ttgttatggt	5400
atagaaataa	aattaaaatt	aaattattat	cgaaatttaa	attttatatt	ttaaagttaa	5460
gtatttaata	attaatagta	tatcgaaggt	tatatatacg	ttaaaaataa	gtaaatttgg	5520
tatatgttat	agtaaaaatat	aggttttttat	tatgaggagt	attgagaagt	atattcgtat	5580
tttttttttt	ttgggtgtatt	ataggtttttt	tttttagtgg	agattttgtcg	ttttattttat	5640
ttttattata	tgatttttaa	ttgtaaaagag	gtttttgatta	agtaaaagttt	attttttataa	5700
aatttgaatt	tatatgttaa	ttaaaatagtt	tttttttttag	tttatattat	gttatgtgat	5760
tatattaata	tatagtaaaa	aattgggtat	tatatatttt	aaattgttag	atgattttta	5820
ataaaaaaat	ttaaattttt	aaaattaatg	gtagtttttt	aaatattatt	gtgataagaa	5880
tatttaatat	taatatatat	aattattttat	ttttatttat	tatttatagt	ttaatatagg	5940
ttagttaatt	tttgtgtaat	gaattttttag	tttttgggat	tagatgtgtt	aggatagaga	6000
gatagataga	gggaggggga	agatagtaat	agtaataaaa	tatttttttta	cgaaatttgt	6060
atataatttt	ttaagtttta	taggtgtaat	tatagttttag	atattttttt	atagtttttt	6120

10613524 seq id 74.txt

gataaataag	tttttttata	atatatgttt	ttagagttat	ttttttgtag	atcggagatg	6180
gttttttttt	taagaattta	attttttatt	agtaaataaa	attaattttt	agtaagtttt	6240
ttttatatag	aattatttta	ggttggtttt	gtggaaaatt	taattgggaa	aaaaagattt	6300
ttaaattatt	atttttttta	agtgtagatt	tttttttaggt	tggttattat	tattttaagg	6360
tgatttttgg	gagttgagaa	aaggatatat	tttttagtcga	atttagtttg	ttagttttcg	6420
tagttattag	taattagttt	tacgttggtt	tttttttttt	tagagattat	agtatttggt	6480
aggtgttttt	ttttttttat	ttttaaagta	acgtttgttt	tttttttttg	aataatgttt	6540
aattgtagaa	ttttataggg	gtgggtttgt	ttgattgttg	cggcggtttt	tatttttggt	6600
aatgttgatt	ataatttttg	ttgtgtttaa	atttgtagta	tttataaaat	atgtttatat	6660
acgcggggga	taattggcga	tgttttttgt	tggttgagg	taggtttggg	aggttttttg	6720
ggggatcgat	ttttcgggta	ggtcggtttg	gttgtttttt	aatacgtatt	tgtttttata	6780
aattatttatt	atttacgggg	aggtggggga	aggatagaga	tgtttatcgg	gtaggggaag	6840
ggaatttttg	gatgtaagga	cgaaaaatga	ggaaagaagg	aaagtagtaa	ggaggaagtt	6900
tttaggaaga	ggaggttatg	ggtgggcgag	ttttggaggg	gaagtaaggg	gtttacgtta	6960
cgaatttttt	tttggtggtg	tagttttggg	ttcgtttaat	ttaattaggg	cggcgtcgac	7020
gagagattat	cggttcgagg	cgtggggttg	tttgattttc	gatttttttt	ttttcggcgt	7080
tagatttttt	taagtccggg	tgtttcggtt	tggggttttt	ttcgttttta	tcgttcgggt	7140
cgttcgcggg	ttgggtttta	tcgtgtgggt	tgccggcggt	gcgttggttg	ttcggagagg	7200
cggtaggggc	atggggggag	gcgggttagt	ttttattttt	tttcgggttg	tttttgatc	7260
gagtttcggg	gaagtttgaa	gttgacgaac	ggcgttggtt	ttatttcggt	ttggaagtta	7320
cgtgcgggag	gagataaaag	aggggttagg	gggagaaagt	tatttagatt	tttttttaa	7380
tttcgttggg	tagcgataat	ttttttttaa	agaaagacgg	aggaagagat	cggggtagta	7440
aaaacgggcg	ttcgggttac	ggttttttag	cgtatattta	cgggcggggc	gcgggtagtt	7500
gtaaagttaa	gtggggtttt	ggcgcgcgag	ttcgcgattc	ggcgggggag	tcgggtcgcg	7560
tcgggggttag	gcgggttacg	ttgtagacgg	ttagtagtcg	ggaggtgggt	ttggatagtt	7620
gagtagggag	ttacgggttac	gttaagtttc	ggtagcgta	gggcggggcg	gtagggtttg	7680
acgggttttcg	ttcgggtttt	cggtaggttag	aagttttttc	gggtcgaggg	tttttcggcg	7740
aggggttttc	ggggtcgcgt	ataattttgt	atggagttcg	gggcgcgtcg	ttcgttcggg	7800
ggtttttttcg	cgtcgcgcgt	tcgattttgt	tcgaggtttc	gtaggtagcg	gtcgttcgcg	7860
ttataggggt	tgtttagggg	cggcgggggt	tcggggatgc	ggcgcggcg	tacggttttt	7920
ttatcggtcg	ggtaggcggc	gggagcggcg	gtcgaaggtt	ttttggttaa	tatggtcgtt	7980
ggagaggaaa	atgtattttt	gggttgctgt	cgtcgtcgct	ggttttgttg	ttatttttgg	8040
cggtcgtcgt	cgtcgttttt	cggtcgtttt	tcgcgcgggt	tttcggcggt	tcgtcgtcgt	8100
ttcgcgtttg	ttatagtttag	atatatatag	tttattgtat	tttttcggtc	ggggttcgtc	8160
gtcgcgagtt	tttcgttttt	tttttcgtcg	tcgttttttt	tttttcggg	cggttgtagt	8220
attttttcggt	tcgtgtatat	gtttcgtttt	tttttcgcg	tcgcgggttt	tttcgttttt	8280
tttatatatg	ggcgcgggga	gttgaagcgt	ttgcgaggat	cgaagatcgt	ttggttcggg	8340
agtttttttc	gggttcgcgc	gcgcgcgttt	tcgcgtattt	atatataggc	gtcggcgcgc	8400
ggtttcgttt	tcgtcgtttt	tcgtcgtttt	ttttcgtcgt	cgtaggtttc	gttttcggtt	8460
ttttcggtcg	cggttacgta	tattttattt	ttatttaatt	tttcgttcgg	ttttttttag	8520
tttttcggtt	tgccgcgtagt	cgttttttcg	tttttcggaa	aattcggcgg	ttttcgttcg	8580
tttttttttcg	tttttttcgg	ttatttggtt	tgtttttttc	ggttttattt	cggcgatttt	8640
ttttttttttt	cggtttcgcg	gcgttttttt	tttgttttat	agtttaattt	atcgttggtg	8700
tttttcggtc	gaaagcgtcg	tagagatttt	ttttttgtta	tgcgattttt	taaataataa	8760
tgtattttta	gttttttcgaa	ttgaatgggt	gtttatagtt	agtattgttt	tttcgttttt	8820
ttatttttgg	tgtagcgat	ttagttattt	tttttttttt	aattattatg	tagatatttt	8880
agttgggcca	gggttatttt	ggcgaggtaa	gttcgggagg	gncggtcgtt	gagttcgttg	8940
ttattttgagta	ggggcgaaaag	agggggttgt	ttttttattt	ttattatata	tttttttcgg	9000
tttattgata	ttaaagtatc	gttcgttagt	cgtaggata	aggggaggta	gagaggcgcg	9060
tgtaggaggt	agttggggaa	gtagttggtt	gtgggttggt	aggtaaaaat	aaatattaga	9120
gatatttttt	atttttttat	aatttcgagt	tttttttttg	cgcggttatt	gggagagata	9180
tattttttttt	ttagttttgc	ggtgagggag	cgatatttcg	aatttttttt	attttatttcg	9240
atatatttttt	tttttttttt	ttttttaaga	tacgtggaga	atttttttgt	tttttttatt	9300
cgttatatat	aatttttttt	ttttttgaag	attaaaaaaa	aattgttttt	tcgtttttata	9360
ttcgcggtttc	gtcgtgcgtg	gtatatagtg	cgtttttggt	taaagggttat	aggtttttgt	9420
attttaattg	tgagaggagg	tggggtggga	aagttcgata	aatttcggat	gacggggtag	9480
agttatgtta	tgtatttttt	tttcgagagg	tgtttagttt	ttgaagtttt	tttggggtta	9540
gggggtttatt	atgttttggt	tcgttcgagt	attttttggt	tttggttgga	tttattgtgt	9600
aggttcgaat	tagttagat	tttagttgga	agggagttat	tttttcggga	gtttttattta	9660
ttttattggt	tgtaaattgt	tatagtaatt	ttttatagag	cgtatttcgta	gtttttatata	9720
aacgttaaaa	attgttttaa	ggtatagtg	gattttttta	gagttttttg	gatttttaaa	9780
gagggttttta	agttagggtt	attgggagag	ggaattttgt	ataaaaagaa	tttttttttag	9840
tattacggtt	ttttaaataa	aataaaaataa	aataaaaataa	aataaaaatat	tttttcgggg	9900

10613524 seq id 74.txt

ttttttttta	ataaagtaga	tttatagtaa	aataatttaa	taatatgttt	ttagaggaat	9960
tatgatttga	attgatttta	gtaagaaata	tttttttatg	tttgttattg	gcgattatta	10020
tatttaaatt	tatatgcgga	agtatattta	gtgttttagaa	tcgattaaaa	gaaaaggggt	10080
attaagtagt	agagatgata	ttagaatcgg	tttttttgatt	tttagtttga	ttttattatg	10140
atttttatta	tattattttt	tttatatttt	taagaaagtt	tatatatttt	tttttttttt	10200
ttaaaataat	tattttttata	ttattttttt	ttttaaaatg	agtattttat	ataattgatg	10260
tttaaatata	aaaatgaagt	aaaaaaatta	attttaatat	aatatgatat	ttttttttgt	10320
ttaagttatt	agtataatat	tttagtagaa	gttaaatatg	ttattgtttt	tttatgaata	10380
aaataaatgt	tagttatttg	aagttatagt	ttacgatttt	taaattagta	atattaattt	10440
atttatttaa	tatgaggaaa	aggagtattg	attttttttt	tttttttttt	ttttgataaa	10500
ggattataat	tattaatttt	aagaaagaaa	aagataatag	ggaatttttt	gtagtatatt	10560
gttttatatt	atgataaata	taattttaat	tttgatatatt	ttttgtggtt	taatataagg	10620
aaatattgta	gttgattttat	tttatagtta	ttttgattat	aaatgggata	tttttgaaaa	10680
ttatattaat	ttttattgat	ttttaagtga	ttattaatta	ttgttttagat	tttttttatt	10740
ttattaaata	ttttattaaa	tattgatatt	tttttgagt	aatgttaaat	agaaaagttg	10800
gataaatata	tttttggggg	tttggggaga	gtgaagtggg	taaatttggg	gagttatttt	10860
ttttaaattt	tattattata	atgtattatt	attaattatt	ttatataatt	atatatattt	10920
tgattttttt	ataaaaatatt	tttataaata	ttattatggt	taatttttat	aattttatta	10980
gagttagatt	tatttttaaat	aggaattttt	ttaaaagttt	tatttagtta	gtaagagatt	11040
gttttttggg	ttttattttat	tgtaaaaatt	ttgtgtgttt	tatatgttta	aaatttagat	11100
ttagataata	aggaggtagg	taggatttag	taggagtaga	gagaaatagg	agaatttaga	11160
atagagtttt	gaggaagaaa	gttgattttt	tattgggtaa	agtattgatt	ataaggaaaa	11220
ttggaaatga	acgtaaaaat	tggtggtttt	aaaatatatt	tatttattta	atttttttat	11280
tttagaaata	tttataaaga	atttagtatg	tgtaggtttt	aggagatatg	atgaattatt	11340
aaatgtagta	gattatattt	tagtttggtt	atttattagg	aattttattt	tgttttgttt	11400
tgtttttggg	tttttgagat	agaattttat	tggtgtgttt	aggttggagt	gtagtggcgt	11460
aatttttagtt	tattgtaatt	tttgttttat	ggtttaagt	gtttttttgt	tttagttttt	11520
cgggtagttg	ggattatagg	tgtttattaa	tacgtttagt	taatttttgt	attttttgta	11580
gagacggggg	tttattacgt	tggttaggtt	ggtttttaat	ttttgatttt	aagtgtatta	11640
tttgtttcgg	ttttttaaag	tgtaggattt	ataggcgtga	gttattatat	ttgttttagga	11700
attttttttt	ttattttaatt	aagtaataag	ttataagaat	ttaatatatt	tttggtatcg	11760
ttgggtggaat	gttatgggtt	gaatgtttgt	gtacgtttta	aattttatatt	ttgaaatttt	11820
aattttataat	gtgatgggtat	taggaggttg	ttagattaag	tgattgtaga	gagttagtag	11880
tttttttttat	tatgtgggga	tatagagagt	aggtattatt	tatgaataag	ggaatagggt	11940
tttattagat	attaaatttg	ttagtattac	gtttttgaat	tttttagttt	ttagaattgt	12000
gagaaataaaa	tttttgtttg	ttatagttat	ttaggttata	gtattttgtt	atagtagttt	12060
taataaataa	agatatgggg	ttatatagtt	aaataatttt	tggttttggt	tattgtttatt	12120
aggaagttta	tagtttcgta	cgggagatta	gatattttaat	gaagtgaata	gagtggtaaa	12180
gaaggatatat	aggagttata	gagatagtat	ataggagaga	gggacgagtt	ttatttaagt	12240
ggtgtttggt	aggggttggt	tttttagtga	ggttttaaa	acgcgtggga	atttgtaagt	12300
taggcgagat	aggttaggat	attttaagt	gaagaaatag	gatgtttaga	agcgttaagt	12360
tgtaagaaag	tatgatgtgt	tttaggggaa	ggggaagtaa	tttagaatag	aggaaatttg	12420
gggtgttagg	tagaggggtg	gtattgttat	ttttttagg	ttaggtttat	ggatagatta	12480
agttagggtta	agaattattt	taaatttggt	taggtatgat	ggtttatggt	tataatttta	12540
gtgttttgag	aagttgagga	gggaggatta	ggagtttgag	attagtttg	ataatatagt	12600
aagattttgt	ttttataaaa	aaagtaaaaa	taaagaaata	ttttaaattt	tatttgttat	12660
ggatatgtga	aaataagggt	taggggtttt	tggagtagtt	agataaatta	ttaaggaatt	12720
gatttatatt	ggtgaagggt	gatttaattt	tttttaagag	aatattaggt	taggtgtagt	12780
ggtttatggt	tgtaatttta	gtattttggg	aggtcgaggc	gggtggatta	tttgaggtta	12840
ggagtttgag	attagtttg	ttaatatagt	gaaattttgt	tgttattaaa	aattttaaaa	12900
aaattagttag	gtatggtggc	gggtatttgt	aatttttagtt	attgggaggt	tgaggtagga	12960
gtattgtttg	aatttaggag	gtggaggttg	tagtgagtta	agattgtgtt	attgtatttt	13020
agtttgggag	atagagtaag	attttattta	aaaaaaaaaa	aaaaaaaaaa	aaaaaagaga	13080
atattattaa	ttggcggtat	tttttatggt	tttattatta	aggtttagaa	tta	13133